 
   
 
 
 
 
  
 
This submission document contains confidential commercial infor mation, disclosure of which 
is prohibited without providing advance notice to AstraZeneca a nd opportunity to object. 
This Clinical Study Protocol ha s been subject to a peer review according to AstraZeneca 
Standard procedures.  The clinical study protocol is publicly r egistered and the results are 
disclosed and/or published according  to the AstraZeneca Global Policy on Bioethics and in 
compliance with prevailing laws and regulations.  Clinical Study Protocol  
 Drug Substance  Benralizumab (Medi-563) 
 Study Code  D3250C00031 
 Version  1.0 
 Date  23 August 2016 
   
A Multicenter, Open-label, Functionality, Reliability and Perfo rmance Study 
of a Single -use Auto-injector with Home-administered Subcutaneous 
Benralizumab in Adult Patients with Severe Asthma (GRECO)  
 
Sponsor: AstraZeneca AB, 151 85 Södertälje, Sweden 
 
Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
 
 
2(83) VERSION HISTORY 
Version 1.0, 23 August 2016 
Initial creation 
 
 
 
 
Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
 
 
3(83) PROTOCOL SYNOPSIS 
 
A Multicenter, Open-label, Functionality, Reliability and Perfo rmance Study 
of a Single -use Auto-injector with Home-administered Subcutaneous 
Benralizumab in Adult Patients with Severe Asthma (GRECO)  
 
 
 
International Coordinating Investigator: 
 
 
 
  
 
 
 
Study sites(s) and number  of subjects planned: 
This study will be conducted in N orth America in approximately 30 study centers.  
Approximately 120 patients will  enter the treatment phase of th e study. 
Study period  Phase of development 
Estimated date of first subject enrolled Q4 2016 Phase 3b 
Estimated date of last subject completed Q4 2017 
 
 
 
 
 
 Redacted
Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
 
 
4(83) Study design 
This is a multicenter, open-label study designed to assess pati ent- or caregiver-reported 
functionality, performance, and reliability of a single-use aut o-injector (AI) with a fixed 30 
mg dose of benralizumab administered subcutaneously (SC) in an at-home setting.   
Approximately 120 adult patients  with severe asthma will enter the treatment period to receive 
5 subcutaneous doses (Week 0, Week 4, Week 8, Week 12, and Week  16) of benralizumab.  
Following a 2 week screening period, eligible patients will rec eive 3 SC doses of 30 mg of 
benralizumab at the study site (Week 0, Week 4, and Week 8). At  Week 0, the Principal 
Investigator or his/her designee will administer the study drug . At Week 4, the patient or 
caregiver will have the option of administering the study drug under study site supervision to 
ensure they understand the procedure and are capable of doing s o.  At Week 8, the patient or 
caregiver will have to perform the injection, again under site staff supervision.  Patients or 
caregivers unable or unwilling to administer investigational pr oduct (IP) at this visit will be 
discontinued from the study.  
The patient or caregiver will be  given the Instructions for Use  (IFU) to refer to for home 
administrations.  The final 2 doses of benralizumab (Week 12 an d Week 16) will be self-
administered by the patient or administered by the caregiver at  home.  After each of these 
administrations, the patient wi ll return for a scheduled on-sit e visit within 48 hours. 
For the at-home administrations, w hether the patient is self-ad ministering or the caregiver is 
administering to a patient, the person administering the dose w ill fill out an administration 
questionnaire designed to indi cate whether the device functione d correctly and the dose was 
successfully administered.  Both t he completed questionnaire an d the used device are to be 
returned to the site during each of the clinic visits (Visit 5 and Visit 6).  The site is to 
subsequently return the used devices and completed questionnair es to the Sponsor for 
evaluation.   
An end-of-treatment (EOT) visi t will be performed at Week 20 an d a follow-up visit at Week 
28 (12 weeks after last IP administration). 
Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
 
 
5(83) Objectives 
Primary objective Outcome measure 
To assess patient- or caregiver-reported 
functionality and reliability of the benralizumab 
single-use auto- injector (AI) 
in an at -home setting and performance of 
the AI device after use.  
 x Proportion of patients/caregivers who 
successfully administered benralizumab 30 mg subcutaneously (SC) by injection 
with an AI device at home  
x Proportion of returned AI device s used to 
administer benralizumab at home that 
have been evalua ted as functional 
x Proportion of AI devices used to 
administer benralizumab at home or in 
the clinic and have been reported as 
malfunctioning (Product Complaints)  
 
Secondary objectives Outcome measure 
To monitor metrics of asthma control  x Change from baseline in mean Asthma 
Control Questionnaire-6 (ACQ- 6) score  
To evaluate the pharmacokinetics, 
pharmacodynamics, and immunogenicity of 
benralizumab  x Pharmacokinetic parameters 
x Peripheral blood eosinophil levels 
x Anti-drug antibodies (ADA)  
 
Safety objectives Outcome measure 
To assess the safety and tolerability of 
benralizumab  x Adverse events (AEs) and serious 
adverse events (SAEs) 
x Laboratory variables 
x Physical examination 
 
Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
 
 
6(83) Target subject population 
Male and female adult patients 18 to 75 years of age with sever e asthma will be enrolled. 
Investigational pro duct, dosage and mode of administration 
Benralizumab 30 mg/mL solution for injection in a single-use au to-injector (AI) will be 
administered at the study center subcutaneously every 4 weeks f or 3 doses (Week 0, Week 4, 
and Week 8) and then at-home every 4 weeks for 2 doses (Week 12  and Week 16). 
Duration of treatment 
Following enrollment, the patien t will enter a 2-week screening  period, followed by a 20 week 
treatment period.  A follow-up visit will be conducted at Week 28. 
The total planned study duration is a maximum of 30 weeks. 
Statistical methods 
The primary endpoints are the proportion of patients/caregivers  who successfully administered 
benralizumab with an AI at home , the proportion of returned AIs  used to administer 
benralizumab at home that have be en evaluated as functional, an d the proportion of AIs used 
to administer benralizumab at home or at the clinic and have be en reported as malfunctioning 
(Product Complaints). Additional  variables include the proporti on of patient/caregivers who 
successfully administered be nralizumab with an AI at both home administrations and the 
proportion of patients/caregivers who have returned AIs used to  administer benralizumab at 
home that have been evaluated as functional at both times. All these endpoints will be 
presented using descriptive statistics and exact 95% confidence  interval (CI) estimates. 
The estimated sample size recruitment of 120 patients is based upon a targeted recruitment 
and successful enrollment of 100 pati ents plus an adjustment to  account for an assumed 
patient dropout rate of approximately 17% (20 patients); theref ore, no hypotheses will be 
tested statistically and the endpoi nts and safety results will be summarized descriptively and 
all data will be listed.
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
7(83) TABLE OF CONTENTS  PAGE 
TITLE PAGE .................................................... ............................................................... ......... 1  
VERSION HISTORY ............................................... ...............................................................  2 
PROTOCOL SYNOPSIS ............................................. ............................................................ 3  
TABLE OF CONTENTS ............................................. ............................................................ 7  
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ................. .......................... 11  
1. INTRODUCTION .................................................. ............................................... 13  
1.1 Background .................................................... ........................................................ 13  
1.2 Rationale for study design, dos es, and control groups ......... .................................. 14  
1.3 Benefit/risk and ethical assessment............................ ............................................ 14  
1.4 Study design .................................................. ......................................................... 15  
2. STUDY OBJECTIVES .............................................. ............................................ 17  
2.1 Primary objective ............................................. ...................................................... 17  
2.2 Secondary objectives .......................................... ................................................... 17  
2.3 Safety objective .............................................. ........................................................ 17  
3. SUBJECT SELECTION, ENROLMENT, TREATMENT, 
RESTRICTIONS, DISCONTINUATION, AND WITHDRAWAL ................. .... 18  
3.1 Inclusion criteria ............................................ ........................................................ 18  
3.2 Exclusion criteria ............................................ ....................................................... 19  
3.3 Subject enrolment and treatment ............................... ............................................ 22  
3.4 Procedures for handling incorr ectly enrolled patients ......... .................................. 22  
3.5 Concomitant medications, restr ictions during and after the stud y ......................... 23  
3.5.1  Concomitant medication ........................................ ................................................ 23  
3.5.2  Restrictions .................................................. .......................................................... 23  
3.6 Discontinuation of investigational product .................... ........................................ 25  
3.7 Criteria for withdrawal ....................................... .................................................... 26  
3.7.1  Screen failures ............................................... ......................................................... 26  
3.7.2  Withdrawal of the informed consent ............................ .......................................... 26  
3.7.3  Discontinuation of the study .................................. ................................................ 26  
4. STUDY PLAN AND TIMING OF PROCEDURES ........................... .................. 27  
4.1 Enrollment and screening period ............................... ............................................ 30  
4.1.1  Enrollment (Visit 1) .......................................... ..................................................... 30  
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
8(83) 4.1.2  Re-screening .................................................. ........................................................ 30  
4.2 Treatment period .............................................. ...................................................... 30  
4.3 Follow-up period .............................................. ...................................................... 31  
5. STUDY ASSESSMENTS ............................................. ........................................ 31  
5.1 Efficacy assessments .......................................... .................................................... 32  
5.1.1  Spirometry .................................................... .......................................................... 32  
5.1.2  Assessment of self and caregiver administration with the single -use auto-
injector ...................................................... ............................................................. 3 4 
5.1.3  Assessment of returned single-use auto-injector device through in vitro 
evaluation .................................................... ........................................................... 34  
5.2 Safety assessments ............................................ ..................................................... 34  
5.2.1  Physical examination .......................................... ................................................... 34  
5.2.2  Vital signs ................................................... ........................................................... 35  
5.2.3  Electrocardiograms ............................................ .................................................... 35  
5.2.4  Laboratory safety assessments ................................. .............................................. 35  
5.3 Other assessments and procedures .............................. ........................................... 37  
5.3.1  Weight and height ............................................. ..................................................... 37  
5.3.2  Patient-reported outcomes ..................................... ................................................ 37  
5.3.3  Other screening assessments ................................... ............................................... 37  
5.3.4  Pharmacokinetics .............................................. ..................................................... 38  
5.3.5  Pharmacodynamics .............................................. .................................................. 38  
5.3.6  Immunogenicity ................................................ ..................................................... 38  
5.3.7  Pharmacogenetics .............................................. .................................................... 38  
5.3.8  Biomarker analysis ............................................ ..................................................... 39  
5.3.9  Handling of biological samples ................................ ............................................. 39  
6. MANAGEMENT OF INVESTIGATIONAL PRODUCT ......................... ........... 39  
6.1 Identity of investigational product(s) ........................ ............................................. 39  
6.2 Labeling ...................................................... ........................................................... 40  
6.3 Storage ....................................................... ............................................................ 40  
6.4 Accountability ................................................ ........................................................ 41  
6.5 Methods for return of used single-use auto-injector devices ... .............................. 41  
6.5.1  Reporting product complaints .................................. .............................................. 41  
6.6 Investigational product administ ration and treatment compliance  ........................ 42  
6.7 Management of investigational product-related reactions ....... .............................. 44  
7. SAFETY REPORTING AND MEDICAL MANAGEMENT ....................... ....... 45  
7.1 Definition of adverse events .................................. ................................................ 45  
7.2 Definitions of serious adverse event .......................... ............................................ 45  
7.3 Recording of adverse events ................................... ............................................... 46  
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
9(83) 7.3.1  Time period for collection of adverse events .................. ....................................... 46  
7.3.2  Follow-up of unresolved adverse events ........................ ........................................ 46  
7.3.3  Variables ..................................................... ........................................................... 46  
7.3.4  Causality collection .......................................... ...................................................... 47  
7.3.5  Adverse events based on signs and symptoms..................... .................................. 47  
7.3.6  Adverse events based on examinations and tests ................ ................................... 48  
7.3.7  Disease progression ........................................... .................................................... 48  
7.3.8  Hy’s Law ...................................................... .......................................................... 48  
7.4 Reporting of serious adverse events............................ ........................................... 48  
7.5 Overdose ...................................................... .......................................................... 49  
7.6 Pregnancy ..................................................... .......................................................... 50  
7.6.1  Maternal exposure ............................................. ..................................................... 50  
7.6.2  Paternal exposure ............................................. ...................................................... 50  
8. STATISTICAL ANALYSES BY ASTRAZENECA ........................... ................. 50  
8.1 Statistical considerations .................................... .................................................... 50  
8.2 Sample size estimate .......................................... .................................................... 51  
8.3 Definitions of analysis sets .................................. .................................................. 51  
8.3.1  All patients analysis set ..................................... ..................................................... 51  
8.3.2  Full analysis set ............................................. ......................................................... 51  
8.3.3  Pharmacokinetic analysis set .................................. ............................................... 51  
8.4 Variables for analyses ........................................ .................................................... 51  
8.4.1  Calculation or derivation  of primary endpoints ................ ..................................... 51  
8.4.2  Calculation or derivation of efficacy variable(s) ............. ...................................... 52  
8.4.3  Calculation or derivation of s afety variable(s) ............... ........................................ 53  
8.4.4  Calculation or derivation of phar macokinetic variables ........ ................................ 53  
8.4.5  Calculation or derivation of immunogenicity variables ......... ................................ 53  
8.5 Methods for statistical analyses .............................. ............................................... 53  
8.5.1  Primary and secondary analysis method(s) ...................... ...................................... 54  
8.5.2  Analysis methods for safety variables ......................... .......................................... 54  
8.5.3  Subgroup analysis ............................................. ..................................................... 55  
9. STUDY AND DATA MANAGEMENT BY ASTRAZENECA ...................... .... 55  
9.1 Training of study center personnel ............................ ............................................ 55  
9.2 Monitoring of the study ....................................... .................................................. 55  
9.2.1  Source data ................................................... .......................................................... 56  
9.2.2  Recording of data ............................................. ...................................................... 56  
9.2.3  Study agreements .............................................. ..................................................... 56  
9.2.4  Archiving of study documents .................................. ............................................. 56  
9.3 Study timetable and end of study .............................. ............................................. 56  
9.4 Data management by AstraZeneca ................................ ........................................ 57  
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
10(83) 10. ETHICAL AND REGULATORY REQUIREMENTS ........................... .............. 57  
10.1  Ethical conduct of the study .................................. ................................................. 57  
10.2  Subject data protection ....................................... .................................................... 58  
10.3  Ethics and regulatory review................................... ............................................... 58  
10.4  Informed consent .............................................. ..................................................... 58  
10.5  Changes to the protocol and informed consent form ............. ................................ 59  
10.6  Audits and inspections ........................................ ................................................... 59  
11. LIST OF REFERENCES ............................................ ........................................... 61  
 
LIST OF TABLES 
Table 1 Study Plan – Enrollment, screening period ............. ................................. 27  
Table 2 Study Plan – Treatment period and follow-up............ .............................. 28  
Table 3 List of safety laboratory tests........................ ............................................ 36  
Table 4 Identity of investigational product ................... ......................................... 39  
 
LIST OF FIGURES 
Figure 1 Study flow chart ..................................... .................................................. 16  
Figure 2 Reversibility testing algorithm ...................... ........................................... 33  
Figure 3 Injection sites and rotation scheme .................. ......................................... 44  
 
LIST OF APPENDICES 
Appendix A ADDITIONAL SAFETY INFORMATION ...................... ...................... 66  
Appendix B INTERNATIONAL AIRLINE TRANSPORTATION 
ASSOCIATION: 6.2 GUIDANCE DOCUMENT ............................ ....... 68  
Appendix C ACTIONS REQUIRED IN CASES OF INCREASES IN LIVER 
BIOCHEMISTRY AND EVALUATION OF HY'S LAW ...................... 69 
Appendix D ANAPHYLAXIS: SIGNS AND SYMPTOMS, MANAGEMENT.........  7 4 
Appendix E PROHIBITED AND RESTRICTED MEDICATIONS .............. ............. 78  
Appendix F BACKGROUND THERAPY EQUIVALENCE TABLE ............... ........ 80  
Appendix G AUTO-INJECTOR ADMINISTRATION QUESTIONNAIRE ......... ..... 81  
 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
11(83) LIST OF ABBREVIATIONS A ND DEFINITION OF TERMS 
The following abbreviations and special terms are used in this study Clinical Study Protocol. 
Abbreviation or 
special term Explanation 
ACQ-6 Asthma Control Questionnaire 6 
ADA Anti-drug antibodies 
AE Adverse event 
ALT Alanine aminotransferase 
AI Auto-Injector 
AST Aspartate aminotransferase 
ATS/ERS American Thoracic Society/European Respiratory Society 
Beta-hCG Beta- human chorionic gonadotropin 
BUN Blood urea nitrogen 
CI Confidence interval 
CO 2 Carbon dioxide 
COPD Chronic obstructive pulmonary disease 
CSA Clinical Study Agreement 
CSP Clinical Study Protocol 
CSR Clinical Study Report 
EC Ethics Committee 
ECG Electrocardiogram 
eCRF Electronic Case Report Form 
ED Emergency department 
EOT End of treatment 
FEV 1 Forced expiratory volume in 1 second 
FSH Follicle-stimulating hormone 
FVC Forced vital capacity 
Gamma-GT Gamma-glutamyl transpeptidase 
GCP Good Clinical Practice 
GINA Global Initiative for Asthma 
GMP Good Manufacturing Practice 
HCP Health care provider 
HIV Human immunodeficiency virus 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
12(83) Abbreviation or 
special term Explanation 
IATA International Air Transport Association 
ICF Informed Consent Form 
ICH International Conference on Harmonisation 
ICS Inhaled corticosteroids 
Ig Immunoglobulin 
IL Interleukin 
IL-5 Interleukin-5 
IL-5R Interleukin-5 receptor 
IL-5Rα Interleukin-5 receptor alpha subunit 
IP Investigational product 
IPD Premature IP Discontinuation 
IVRS Interactive Voice Response System 
IWRS Interactive Web Response System 
LABA Long-acting β 2 agonists 
LTRA Leukotriene receptor antagonists 
MedDRA Medical Dictionary for Regulatory Activities 
nAb 
OAE Neutralizing antibody 
Other significant adverse event 
PK Pharmacokinetic(s) 
PRO Patient reported outcome 
RBC Red blood cell 
SABA Short-acting β 2 agonists 
SAE Serious adverse event  
SAP Statistical Analysis Plan 
SC Subcutaneous  
SUSARs Suspected Unexpected Serious Adverse Reactions 
ULN Upper limit of normal 
UNS Unscheduled 
WBC White blood cell 
WBDC Web-based Data Capture 
WOCBP Women of childbearing potential 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
13(83) 1. INTRODUCTION 
1.1 Background  
Asthma is a syndrome characterized by airway inflammation, reve rsible airway obstruction, 
and airway hyperresponsiveness.  Patients present clinically wi th recurrent wheezing, 
shortness of breath, cough, and chest tightness.  Asthma is a l eading cause of morbidity with a 
global prevalence of approximately 300 million; it is estimated  that the number of people with 
asthma may increase to 400-450 million people worldwide by 2025  (Masoli et al 2004). 
The current approach to anti-infl ammatory controller therapy in  asthma is based on a 
step-wise intensification of a daily maintenance regimen primar ily centered around inhaled 
corticosteroids (ICS) and leukotriene receptor antagonists (LTR A), with the addition of long-
acting β 2 agonists (LABA) in patients with more severe asthma (GINA 2016 , NAEPP 2007).  
Despite treatment per management guidelines, up to 50% of patie nts have asthma that is not 
well-controlled (Bateman et al 2010).  This results in consider able impact on quality of life, 
disproportionate use of healthcare resources, and adverse react ions from regular systemic 
steroid use.  Therefore, there remains an unmet medical need fo r patients whose asthma is not 
controlled by existing therapies. 
The observed variability in clin ical response to currently avai lable asthma therapies appears to 
be related, in part, to distinctive inflammatory phenotypes (We nzel 2012).  In particular, 
asthma associated with eosino philic inflammation in the airway (often referred to as 
eosinophilic asthma) is common (approximately 40% to 60% of ast hmatics) with the degree of 
eosinophilia associated with clinical severity including the ri sk of asthma exacerbations 
(Bousquet et al 1990; Louis et al 2000; Di Franco et al 2003; S cott and Wardlaw 2006, 
Simpson et al 2006; Zhang and Wenzel 2007).  
Interleukin-5 (IL-5) is a key cytokine essential for eosinophil  trafficking and survival 
(Molfino et al 2011). Benralizumab (MEDI-563) is a humanized, a fucosylated, monoclonal 
antibody that binds specifically to the human IL-5 receptor alp ha subunit (IL-5Rα) on the 
target cell.  The IL-5 receptor (IL-5R) is expressed almost exc lusively on the surface of 
eosinophils and basophils (Taka tsu et al 1994; Toba et al 1999) .  Afucosylation confers 
enhanced antibody-dependent cel lular cytotoxicity (ADCC) which results in highly efficient 
eosinophil depletion by apoptosis (Kolbeck et al 2012).  Single  and repeated doses of 
benralizumab in mild to severe asthma patients has resulted in depletion of blood and airway 
eosinophils (Busse et al 2010, Gossage et al 2012, Molfino et a l 2012).  Also, a recent dose 
finding trial in severe asthma  proved benralizumab to have bene fit across a range of asthma 
outcomes including reductions in asthma exacerbations, improvem ents in lung function, and 
reduction in symptoms (Castro et al 2014). 
The efficacy and safety of benralizumab has been confirmed in t wo large phase 3 trials, in 
severe asthmatics with a history of exacerbations, still sympto matic despite using medium-to-
high dose ICS/LABAs with or without oral corticosteroids or add itional controller 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
14(83) medications. (Bleecker et al 2016, FitzGerald et al 2016). The dose studied in these trials was 
30 mg, a dose derived from pharmacokinetic/pharmacodynamic (PK/ PD) modelling of the 
Phase 2 dose finding study, administered in 2 dosing regimens –  either 30 mg every 4 weeks 
(Q4W) or 30 mg every 4 weeks (Q4W) for the first 3 doses follow ed by dosing every 8 weeks 
(Q8W) thereafter. The primary endpoint in each study was the an nual rate of asthma-related 
exacerbations with key secondary endpoints being FEV 1 and asthma symptoms as defined by 
a daily patient diary.  
The purpose of this study is to assess patient-or caregiver-rep orted functionality, performance, 
and reliability of a single-use auto-injector device used to ad minister a fixed 30 mg dose of 
benralizumab subcutaneously (SC) in an at-home setting.  
1.2 Rationale for study design, doses, and control groups 
This is a multicenter open-label  functionality, reliability and  performance study of a single-use 
auto-injector with benralizumab. T he primary endpoints will be the proportion of 
patients/caregivers who success fully administered benralizumab SC with an AI, the proportion 
of returned AI device used to administer benralizumab at home t hat have been evaluated as 
functional, and the proportion of AI  device used to administer benralizumab at home or at the 
clinic and have been reported as malfunctioning (Product Compla ints). 
The benralizumab dose (30 mg SC, fixed) is based on population exposure-response 
modeling, and stochastic trial simulations from earlier benrali zumab trials. The dosing 
regimen chosen, every 4 weeks (Q4W), is used in the pivotal Pha se 3 efficacy and safety 
studies. Other stable asthma therapies on top of inhaled cortic osteroids/long-acting β 2 agonists 
(ICS/LABA) that are within exp ert guidance and that are not res tricted per protocol (see 
Section 3.5.2) are allowed in order to accommodate local standa rds of care. 
1.3 Benefit/risk and ethical assessment 
Benralizumab is primarily being studied in severe asthma where there are few treatment 
options for patients whose asthma remains uncontrolled on high dose ICS/LABA and oral 
corticosteroids (GINA 2016).  In a dult patients whose asthma wa s poorly controlled on 
medium-to-high dose ICS/LABA therapy, benralizumab at doses of ≥20 mg produced 
improvements in multiple metrics of a sthma control including th e annual rate of asthma 
exacerbations, lung function, ACQ-6 scores, and symptoms (Castr o et al 2014). These 
findings have subsequently bee n confirmed in two large Phase 3 studies (Bleecker et al 2016, 
FitzGerald et al 2016) where a fixed dose of 30 mg was given ei ther Q4W or Q8W. 
 Development of anti-drug antibodies (ADA) to benralizumab has b een documented. 
Theoretical risks of developing ADA include decreased drug effi cacy and hypersensitivity 
reactions (eg, anaphylaxis or immune complex disease). Eosinoph ils are a prominent feature 
of the inflammatory response to he lminthic parasitic infections  and the presence of infiltrating 
eosinophils has been circumsta ntially associated with a positiv e prognosis in certain solid 
tumors. Therefore, there is a theoretical risk that prolonged e osinophil depletion may diminish 
the ability to defend against helminthic parasites, or negative ly impact the natural history of 
certain malignant tumors. Risk min imization measures herein inc lude exclusion of patients 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
15(83) with untreated parasitic infect ion and active or recent maligna ncy, in conjunction with the 
performance of routine pharmacovigilance activities.  The efficacy and safety data obtained to date support the conti nued clinical development of 
benralizumab in patients with asthma.   
The purpose of this trial is to c onfirm the successful use of b enralizumab in an AI in an at-
home setting by the patient or caregiver. A detailed assessment  of injection site reactions and 
the overall risk/benefit of benralizumab in patients with asthm a is given in the Investigator’s 
Brochure (IB). 
1.4 
Study design 
This is a multicenter, open-label study designed to assess pati ent- or caregiver-reported 
functionality, performance, and reliability of a single-use aut o-injector (AI) with a fixed 30 
mg dose of benralizumab administered subcutaneously (SC) in an at-home setting.   
Approximately 120 adult patients  with severe asthma will enter the treatment period to receive 
5 subcutaneous doses (Week 0, Week 4, Week 8, Week 12, and Week  16) of benralizumab.  
Following a 2 week screening period, eligible patients will rec eive 3 SC doses of 30 mg of 
benralizumab at the study site (Week 0, Week 4, and Week 8) (Fi gure 1). At Week 0, the 
Principal Investigator or his/her designee will administer the study drug. At Week 4, the 
patient or caregiver will have the option of administering the study drug under study site 
supervision to ensure they understand the procedure and are cap able of doing so.  At Week 8, 
the patient or caregiver will have to perform the injection, ag ain under site staff supervision.  
Patients or caregivers unable or unwilling to administer invest igational product (IP) at this 
visit will be discontinued from the study.  
The patient or caregiver will be  given the Instructions for Use  (IFU) to refer to for home 
administrations.  The final 2 doses of benralizumab (Week 12 an d Week 16) will be self-
administered by the patient or administered by the caregiver at  home.  After each of these 
administrations, the patient wi ll return for a scheduled on-sit e visit within 48 hours. 
For the at-home administrations, w hether the patient is self-ad ministering or the caregiver is 
administering to a patient, the person administering the dose w ill fill out an administration 
questionnaire designed to indi cate whether the device functione d correctly and the dose was 
successfully administered.  Both t he completed questionnaire an d the used device are to be 
returned to the site during each of the clinic visits (Visit 5 and Visit 6).  The site is to 
subsequently return the used devices and completed questionnair es to the Sponsor for 
evaluation.   
An end-of-treatment (EOT) visit will be performed at Week 20 an d a follow-up visit at Week 
28 (12 weeks after last IP administration). 
 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
16(83) Figure 1 Study flow chart 
 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
17(83) 2. STUDY OBJECTIVES 
2.1 Primary objective 
Primary objective Outcome measure 
To assess patient- or caregiver-reported 
functionality and reliability of the benralizumab single
-use auto- injector (AI) 
device in an at -home setting and 
performance of the AI device after use.  
 x Proportion of patient s/caregivers who 
successfully administered benralizumab 30 mg subcutaneously (SC) by injection 
with an AI device at home  
x Proportion of returned AI devices used to 
administer benralizumab at home that 
have been evalua ted as functional 
x Proportion of AI device used to 
administer benralizumab at home or in 
the clinic and have been reported as 
malfunctioning (Product Complaints)  
 
2.2 Secondary objectives 
Secondary objectives Outcome measure 
To monitor metrics of asthma control x Change from baseline in mean Asthma 
Control Questionnaire-6 (ACQ- 6) score  
To evaluate the pharmacokinetics, 
pharmacodynamics, and immunogenicity of benralizumab
 x Pharmacokinetic parameters 
x Peripheral blood eosinophil levels 
x Anti-drug antibodies (ADA)  
 
2.3 Safety objective  
Safety objectives Outcome measure 
To assess the safety and tolerability of 
benralizumab  x Adverse events (AEs) and serious 
adverse events (SAEs) 
x Laboratory variables 
x Physical examination 
 
 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
18(83) 3. SUBJECT SELECTION, E NROLMENT, TREATMENT, 
RESTRICTIONS, DISCONTI NUATION, AND WITHDRAWAL  
Each subject should meet all of t he inclusion criteria and none  of the exclusion criteria for this 
study. Each caregiver should meet the applicable inclusion crit eria for this study. Under no 
circumstances can there b e exceptions to this rule. 
  
3.1 Inclusion criteria 
For inclusion in the study subj ects should meet the following c riteria: 
1. Written informed consent for study participation must be obtain ed prior to any study 
related procedures being performed and according to internation al guidelines and/or 
applicable European Union (EU) guidelines.  
2. Male and female patients aged 18 to 75 years of age at the time  of Visit 1. 
3. Patient or caregiver must be will ing and able to administer the  IP. Caregiver must be age 
of consent or older at the time of Visit 1, if applicable.  
4. Women of childbearing potential (WOCBP) must use an effective f orm of birth control 
(confirmed by the Investigator). Effective forms of birth contr ol includes: true sexual 
abstinence, a vasectomised sexual partner, Implanon ®, female s terilization by tubal 
occlusion, any effective IUD Int rauterine device/IUS Ievonorges trel Intrauterine system, 
Depo-Provera™ injections, oral contraceptive, and Evra Patch™ o r Nuvaring™. 
WOCBP must agree to use birth co ntrol, as defined above, from e nrollment, throughout the 
study duration and until 16 weeks after last dose of investigat ional product (IP). WOCBP 
must also have negative serum pre gnancy test result on Visit 1.   
Women not of childbearing potential are defined as women who ar e either permanently 
sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are 
postmenopausal. Women will be considered postemenopausal if the y have been 
amenorrheic for 12 months prior  to the planned date of Visit 2 without an alternative 
medical cause. The following age-specific requirements apply: 
 Women <50 years old are considered postmenopausal if they have been amenorrheic 
for 12 months or more following cessation of exogenous hormonal  treatment and 
follicle stimulating hormone (FSH) levels in the postmenopausal  range 
 Women ≥50 years old are considered postmenopausal if they have been amenorrheic 
for 12 months or more following cessation of all exogenous horm onal treatment 
5. All male patients who are sexually active must agree to use a d ouble barrier method of 
contraception (condom with spermic ide) from the first dose of I P until 16 weeks after 
their last dose 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
19(83) 6. Weight of ≥40 kg 
7. Evidence of asthma as documented by airway reversibility (FEV 1 >12% and 200 ml) 
demonstrated at Visit 1 or 1A or Visit 2 
If patients do not demonstrate airway reversibility at either V isit 1 or 1A or Visit 2 the 
patient must not enter the treat ment period and must be rescree ned, if appropriate. If re-
screened, the study center should reiterate the need to withhol d short- and long-acting 
bronchodilators as required in Section 5.1.1 prior to spirometr y visits in an effort to meet 
this inclusion criterion. Visit 1A is optional for additional m easurements if patient is on 
bronchodilators at the time of Visit 1. 
8. Documented history of current treatment with ICS and LABA.  The  ICS and LABA can 
be parts of a combi nation product or given by separate inhalers .  The ICS dose must be 
greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or 
equivalent daily.  Equivalents for fluticasone dry powder can b e found in Appendix F. 
 For ICS/LABA combination preparations, both the mid- and high-s trength 
maintenance doses approved in the local country will meet this ICS criterion. 
 Additional asthma controller medications (e.g., LTRAs, tiotropi um, theophylline, 
oral corticosteroids) are allowed (see Section 3.5.2.1 for rest ricted therapies)   
9. Pre-bronchodilator (pre-BD) FEV 1 of >50% predicted normal at Visit 1 or 1A or Visit 2 
10. Not well-controlled asthma as documented by either  
– An ACQ6  >1.5 OR 
– A peak expiratory flow of 60-80% predicted normal OR 
– One or more exacerbation that required oral or systemic cortico steroids in the 
previous year 
Inclusion criteria at star t of Treatment Period  
11. For WOCBP only: Have a negative urine pregnancy test prior to a dministration of the IP 
at day of Visit 2 (Week 0) 
3.2 Exclusion criteria 
Patients must not enter the study if any of the following exclu sion criteria are fulfilled: 
1. Clinically important pulmonary disease other than asthma (eg, a ctive lung infection, 
chronic obstructive pulmonary disease (COPD), bronchiectasis, p ulmonary fibrosis, 
cystic fibrosis, hypoventilation syndrome associated with obesi ty, lung cancer, alpha 1 
anti-trypsin deficiency, and primary ciliary dyskinesia) or eve r been diagnosed with 
pulmonary or systemic disease, other than asthma, that are asso ciated with elevated 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
20(83) peripheral eosinophil counts (eg, allergic bronchopulmonary asp ergillosis/mycosis, 
Churg-Strauss syndrome, hypereosinophilic syndrome) 
2. Any disorder, including, but not  limited to, cardiovascular, ga strointestinal, hepatic, 
renal, neurological, musculoske letal, infectious, endocrine, me tabolic, hematological, 
psychiatric, or major physical impairment that is not stable in  the opinion of the 
Investigator and could: 
 Affect the safety of the patient throughout the study 
 Influence the findings of the studies or their interpretations 
 Impede the patient’s ability to complete the entire duration of  study 
3. Known history of allergy or rea ction to the IP formulation 
4. History of anaphylaxis to any biologic therapy 
5. History of Guillain-Barré syndrome 
6. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed 
consent is obtained that has not been treated with, or has fail ed to respond to standard of 
care therapy 
7. Acute upper or lower respiratory infections requiring antibioti cs or antiviral medication 
within 30 days prior to the date informed consent is obtained o r during the screening 
8. Any clinically significant abnormal findings in physical examin ation, vital signs, 
hematology, clinical chemistry, or urinalysis during screening period, which in the 
opinion of the Investigator, may put the patient at risk becaus e of his/her participation in 
the study, or may influence the results of the study, or the pa tient’s ability to complete 
entire duration of the study 
9. Any clinically significant cardiac disease or any electrocardio gram (ECG) abnormality 
obtained during the screening/run-in period, which in the opini on of the Investigator may 
put the patient at risk or interfere with study assessments 
10. History of alcohol or drug abuse within 12 months prior to the date informed consent is 
obtained 
11. Positive hepatitis B surface antigen, or hepatitis C virus anti body serology, or a positive 
medical history for hepatitis B or C.  Patients with a history of hepatitis B vaccination 
without history of hepatitis B are allowed to enroll 
12. A history of known immunodeficiency disorder including a positi ve human 
immunodeficiency virus (HIV) test 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
21(83) 13. Current smokers or former smoke rs with a smoking history of ≥10  pack years. A former 
smoker is defined as a patien t who quit smoking at least 6 mont hs prior to Visit 1. 
14. History of cancer: 
 Patients who have had basal cell c arcinoma, localized squamous cell carcinoma of 
the skin or in situ carcinoma of the cervix are eligible provid ed that the patient is in 
remission and curative therapy was  completed at least 12 months  prior to the date 
informed consent was obtained 
 Patients who have had other maligna ncies are eligible provided that the patient is in 
remission and curative therapy was completed at least 5 years p rior to the date 
informed consent was obtained 
15. Use of immunosuppressive medication (including but not limited to: oral corticosteroid 
[for reasons other than asthma], methotrexate, troleandomycin, cyclosporine, 
azathioprine, intramuscular long-acting depot corticosteroid [f or reasons other than 
asthma], or any experimental anti-inflammatory therapy) within 3 months prior to the 
date informed consent. 
16. Current use of an oral or ophthalmic non-selective β-adrenergic  antagonist (eg, 
propranolol) 
17. Alanine aminotransferase (ALT) or aspartate aminotransferase (A ST) level ≥1.5 times 
the upper limit of normal (ULN) confirmed during screening peri od. 
18. Five- lipoxygenase inhibitors ( eg, Zileuton) and roflumilast ar e prohibited. 
19. Receipt of immunoglobulin or blood products within 30 days prio r to the date informed 
consent is obtained. 
20. Receipt of any marketed (eg, omaliz umab, mepolizumab etc) or in vestigational biologic 
within 4 months or 5 half-lives prior to the date informed cons ent is obtained, whichever 
is longer 
21. Receipt of live attenuated vaccines 30 days prior to the date o f Visit 2 (Week 0) 
 Receipt of inactive/kill ed vaccinations (eg, inactive influenza ) is allowed provided 
they are not administered within 1 week before/after any invest igational product 
administration.  
22. Receipt of any investigational non-biologic within 30 days or 5  half-lives prior to Visit 2 
whichever is longer 
23. Previously received benralizumab (MEDI-563)  
24. Initiation of new allergen immunotherapy is not allowed within 30 days prior to the date 
of informed consent. Immunotherapy  initiated prior to this peri od or as a routine part of 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
22(83) the patient’s seasonal treatment is allowed.  If the immunother apy is delivered as an 
injection, there should be a gap of 7 days between the immunoth erapy and IP 
administration.  
25. Planned surgical procedures during the conduct of the study 
26. Currently breastfeeding or lactating women 
27. Concurrent enrollment in another drug-related interventional cl inical trial or post-
authorization safety study (PASS) 
28. AstraZeneca staff involved in the planning and/or conduct of th e study 
29. Employees of the study center or any other individuals involved  with the conduct of the 
study, or immediate family members of such individuals 
3.3 Subject enrolment and treatment  
Investigator(s) should keep a re cord of patients considered for  and included in the study.  This pre-
screening/screening log will be evaluated periodically by Astra Zeneca or its delegates during 
routine monitoring visits. 
The Investigator will: 
1. Obtain signed informed consent  from the potential patient and c aregiver if applicable, 
before any study specific procedures are performed. 
2. Assign each potential patient a unique enrollment number, begin ning with E# via 
interactive web/voice response system (IWRS/IVRS) 
3. Determine patient eligibility 
If a patient withdraws from participation in the study, then hi s/her enrolment code cannot be reused. 
Specific information concerning the use of the IWRS/IVRS will b e provided in the separate 
manual.  
3.4 Procedures for handling incorrectly enrolled patients 
Patients who fail to meet the eli gibility criteria should not, under any circumstances, be enrolled or 
receive study medication.  There can be no exceptions to this r ule.  Patients who are enrolled, but 
subsequently found not to meet all the eligibility criteria mus t not be initiated on treatment, and 
must be withdrawn from the study. 
Where a patient does not meet all the eligibility criteria, but  is incorrectly started on treatment, the 
Investigator should inform the AstraZeneca Study Physician imme diately, and a discussion should 
occur between the AstraZeneca Study Physician and the Investiga tor regarding whether to continue 
or discontinue the patient from t reatment.  The AstraZeneca Stu dy Physician must ensure all 
decisions are appropriately documented. 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
23(83) 3.5 Concomitant medications, restrictions during and after the stud y 
3.5.1 Concomitant medication 
Information about any treatment in the 3 months prior to the da te of the informed consent and all 
the concomitant treatments given during the study with reason f or the treatment will be collected by 
the Investigator/authorized delegate at each visit (as shown in  Table 1 and Table 2) and recorded in 
the electronic Case Report Form (eCRF). 
Note : To satisfy inclusion criterion 8 (Section 3.1), the history o f treatment with asthma therapies at 
the protocol designated dos es prior to Visit 1 should be docume nted in source and recorded in the 
eCRF (see Section 4.1.1). 
3.5.1.1  Background medication  
Background asthma medications may  be increased from Visit 2 thr ough 8 at the discretion of the 
Investigator to improve the patient’s asthma control, if needed . If the addition of a new asthma 
controller therapy or a change i n dose of any asthma medication (s) is judged by the Investigator as 
necessary, the justification s hould be documented in the source  and in the eCRF.   
A step down in therapy is discouraged and must be discussed bef orehand with the AstraZeneca 
Study Physician. 
3.5.1.2  Rescue medication  
Short-acting bronchodilators (SABAs) may be used as rescue medi cation during the study. 
The patient is to be prescribed a n epinephrine-containing devic e (eg, EpiPen®) for use in the event 
of an allergic reaction and trained by the study center on its use (see Table 2).  If a caregiver is 
administering the IP, the caregiver must also be trained on its  use. 
3.5.2 Restrictions 
3.5.2.1  Asthma medication restrictions 
(a) Use of long-acting beta-agonists as a  reliever (eg, Symbicort Maintenance and Reliever 
Treatment) is not allowed from e nrollment and throughout the st udy duration 
(b) Use of short-acting anticholinergics  (eg, ipratropium) as a rescue treatment for 
worsening asthma symptoms is not allowed from enrolment and thr oughout the study 
duration. 
(c) Use of short-acting beta-agonists 
Regularly scheduled or prophylactic SABA use is discouraged fro m enrolment and 
throughout the study duration.   
(d) Maintenance of asthma controller medications  
Any and all changes to the pati ent’s background medication shou ld be recorded in an 
eCRF and documented in source rec ords along with a rationale fo r the change.   
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
24(83) Asthma exacerbations should be treated with oral or other syste mic corticosteroids 
according to standard practice. 
(e) Asthma medication restrictions on the days of scheduled spirome try visit 
Pre- and/or post-BD spirometry assessments will be performed at  the study center at 
scheduled visits (see Table 1  and Table 2): restrictions to patient’s background 
medication are required prior to t he spirometry as described be low: 
Visit 1 or 1A or 2: Patients should withhold their usual ICS-LABA medications on th e 
day(s) when reversibility testing is being performed.  
Twice daily ICS and LABA therapies should be withheld for 12-24  hours; once daily therapies 
containing ICS, LABA, or LAMA t herapies should be withheld for ≥24 hours for eligibility 
assessment. In addition, SABA should not be used within 6 hours  of these spirometry assessments. 
The patient’s usual asthma med ications may be administered foll owing completion of the lung 
function procedures.  
3.5.2.2  Other medication restrictions  
(a) Use of immunosuppressive medication or administration of live/a ttenuated vaccines is 
not allowed.  Topical administration of immunosuppressive medic ation may be allowed 
at the discretion of the Investi gator after discussion with the  AstraZeneca Study 
Physician.  Please see Section 3.2 exclusion criterion 15 for e xamples and further details. 
(b) Receipt of live attenuated vaccines within 30 days prior to Vis it 2, during the treatment 
period, and for 16 weeks (5 half-lives)  after the last dose of the IP is not allowed 
(c) Patient should not receive allergen immunotherapy injection on the same day as the IP 
administration 
(d) When enrolling a patient who is on theophylline, digoxin, or ot her drugs with a narrow 
therapeutic range, the Investigator should ensure the levels of  each of these medications 
must not exceed the upper limit of t herapeutic range.  The Inve stigator will also be 
responsible for ensuring that these levels are regularly checke d and documented as per 
local practice (see Table 1) 
(e) Patients should not take any ot her excluded medications: 
 Five-lipoxygenase inhibitors (eg, Zileuton) 
 Roflumilast 
 Oral or ophthalmic non-selective β-a drenergic antagonist (eg, p ropranolol). 
A table with medication-related restrictions presented in the A ppendix E. 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
25(83) 3.5.2.3  Other restrictions 
(a) Fertile and sexually active pa tients or their partners should u se highly effective 
contraceptive methods throughout the study and at least for 16 weeks (5 half-lives) after 
last administration of the IP .  Male patients should refrain fr om fathering child or 
donating sperm from the time  of informed consent, and for 16 we eks (5 half-lives) after 
last dose of IP (see Section 3.1, inclusion criteria 4 and 5; a nd Section 7.6) 
(b) Patients must abstain from donating blood or plasma from the ti me of informed consent 
and for 16 weeks (5 half-lives) after the last dose of IP. 
3.6 Discontinuation of investigational product  
Patients will be discontinued from  IP in the following situatio ns: 
1. Patient decision.  The patient is  free to discontinue treatment  at any time without 
prejudice to further treatment. 
2. Adverse event (AE) that, in the opinion of the Investigator, co ntraindicates further dosing 
3. Risk to patient as judged by the  Investigator or AstraZeneca 
4. Severe non-compliance to study protocol 
5. Eligibility requirement found not to be fulfilled (see Section 3.4) 
6. Pregnancy 
7. Lost to follow-up1 
8. Development of any study specific criteria for discontinuation:  
1. Anaphylactic reaction to the IP requiring administration of epi nephrine 
2. Development of helminth parasitic infestations requiring hospit alization 
3. An asthma-related event requiring mechanical ventilation. 
9. A patient who is self-administering IP who becomes unwilling or  unable to continue to 
self-administer must be discontinued.  Similarly, if a caregive r is giving the IP and 
becomes unwilling or unable to continue to administer IP to a p atient, then that patient 
must be discontinued.   
All patients who prematurely discontinue IP should return to th e study center and complete the 
procedures described for the Premature IP Discontinuation (IPD)  visit after 4 weeks (±3 days) and 
                                                 
1 Patient is considered lost to follow up when any of the follow ing attempts of contact are failed: -3 attempts of either 
phone calls, faxes or emails; - having sent 1 registered letter /certified mail; 1 unsuccessful effort to check the vital 
status of the patient using publicly available sources, if allo wed by local regulations. 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
26(83) the procedures for the Follow-up visit after 12 weeks (±3days) of the last IP administration.  The 
reason(s) for premature discontinuation of IP should be recorde d in the eCRF. 
3.7 Criteria for withdrawal 
3.7.1 Screen failures  
Screen failures are patients  who do not fulfill the eligibility  criteria for the study and therefore must 
not enter the treatment part of  the study.  These patients shou ld have the reason for study 
withdrawal recorded as ‘Incorr ect Enrollment’ (ie, patient does  not meet the required 
inclusion/exclusion criteria).  This reason for study withdrawa l is only valid for screen failures (not 
patients in the treatment phase). 
3.7.2 Withdrawal of the informed consent 
Patients or caregivers, if applicable, are free to withdraw fro m the study at any time (IP and 
assessments) without prejudice to further treatment. 
A patient who withdraws consent will always be asked about the reason(s) and the presence of any 
AE.  The Investigator will follow up with AEs outside of the cl inical study.   
The enrollment code of the withdra wn patient cannot be reused. Withdrawn subjects will not be 
replaced. 
3.7.3 Discontinuation of the study 
The study may be stopped if, in the judgment of AstraZeneca, tr ial subjects are placed at 
undue risk because of clinically significant findings that: 
x meet individual stopping criteria or are otherwise considered s ignificant 
x are assessed as causally related to study drug, 
x are not considered to be consistent with continuation of the st udy 
Regardless of the reason for ter mination, all data available fo r the subject at the time of 
discontinuation of follow-up must  be recorded in the eCRF. All reasons for discontinuation of 
treatment must be documented.  
In terminating the study, the Sponsor will ensure that adequate  consideration is given to the 
protection of the subjects’ interests. 
 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
27(83) 4. STUDY PLAN AND TIMI NG OF PROCEDURES 
Table 1 Study Plan – Enrollment, screening period 
Assessment/ activity  Refer to  Screening 
V1 (W –2) V1Ad (V1 + max. 3 days) 
Informed consent 10.4 X  
Inclusion/exclusion criteria 3.1/3.2 X  
Medical and asthma history 4.1.1 X  
Complete physical examination 5.2.1.1 X  
Weight, Height, BMI 5.3.1 X  
Vital Signs 5.2.2 X  
Local ECG 5.2.3 X  
Serum chemistry  5.2.4 X  
Hematology  5.2.4 X  
Urinalysis 5.2.4 X  
Blood concentration (digoxin, 
theophylline) a 3.5.2.2  X   
Serology  
(hepatitis B,C; HIV-1; HIV-2) 5.3.3.1  X   
Serum pregnancy test 5.2.4.1 X  
FSH b 5.2.4.1  X   
Adverse events 7.1 X  
Concomitant medication 3.5 X  
ACQ-6 at Study Center 5.3.2.1 X  
Pre- and post-bronchodilator 
spirometryc  5.1.1  X  Xd 
Review of the AI IFU and the 
Administration Questionnaire 6.6 X   
Training on epinephrine-containing 
device 3.5.1.2  X   
a If and when appropriate prior to t reatment period; for patients  who are on theophylline or digoxin, (see Section 
3.5.2.2) 
b FSH test done only for female patients to confirm postmenopaus al status in women <50 years who have been 
amenorrheic for >12 month 
c Pre- and post-bronchodilator spirometry can be done at Visit 1 ( or optional Visit 1Ad) OR Visit 2 
d  Visit 1A is optional for spirometry measurement only 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
28(83) Table 2 Study Plan – Treatm ent period and follow-up 
Assessment/ activity  Refer to Treatment 
 EOT IPD FU Unsch 
V2 V3 V4 V5 V6 V7  V8  
W0 W4 W8 W12 W16 W20  W28  
Visit window (days) a 
±3 ±3 ±3 ±3h ±3h ±3 ±3 ±3 N/A 
Inclusion/exclusion criteria 3.1/3.2 X         
Review of the AI IFU and 
Questionnaire 6.6 X X X Xb Xb    Xb 
Training on epinephrine-containing 
device 3.5.1.2 X X X X     Xb 
Complete physical examination 5.2.1.1 X     X X X  
Brief physical examination 5.2.1.2  X X X X    X 
Vital Signs 5.2.2 X X X X X X X X X 
Serum chemistry  5.2.4 X     X X X  
Hematology  5.2.4 X     X X X  
Urinalysis 5.2.4 X     X X X  
Urine pregnancy test (dipstick) c 5.2.4.1 X X X X X X X X  
At-home urine pregnancy test before IP 
administrationc 5.2.4.1    X X     
PK 5.3.4 X*  X*   X X X  
ADA/nAbj 5.3.6 X*  X*   X X X  
ACQ-6 at Study Center 5.3.2.1 X X X X X X X   
Pre- and post- bronchodilator spirometryi  5.1.1 X         
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
29(83) Table 2 Study Plan – Treatm ent period and follow-up 
Assessment/ activity  Refer to Treatment 
 EOT IPD FU Unsch 
V2 V3 V4 V5 V6 V7  V8  
W0 W4 W8 W12 W16 W20  W28  
Visit window (days) a 
±3 ±3 ±3 ±3h ±3h ±3 ±3 ±3 N/A 
Adverse events 7.1 X X X X X X X X X 
Concomitant medication 3.5 X X X X X X X X X 
IP Admi nistration at site g 6.6 Xd Xe Xe       
IP Administration at home g 6.6    Xe Xe     
Visit Reminder Call f 6.6    X X     
Return of AI and admin. questionnaire 6.5    X X     
a All visits are to be scheduled  from the date of Visit 2 but no t from the date of previous visit except in the case of early d iscontinuation from IP (see 
Section 3.6 for details). 
b At those Visits training/review with the patient is optional.  
c For WOCBP only, a urine HCG test must be done prior to IP admi nistration at Visits 2 (Week 0) , 3 (Week 4), and 4 (Week 8) at the study center.  
At-home urine pregnancy tests ar e to be done by WOCBP prior to IP administration at Weeks 12 and 16 and repeated by the center  staff at Visits 5 
and 6.  In the case of a positiv e test, the patient is NOT to a dminister IP and is to call the study center.  Urine pregnancy tests will be done at the 
study center at the EOT visit (Visit 7, Week 20) and the Follow -up visit (Visit 8, Week 28).   
d Study drug will be administered  on site by HCP in either the a rm, thigh, or abdomen 
e At Visit 3, the patient/caregiver has the option to administer the study drug.  At Visits 4 , 5, and 6, the patient/caregiver m ust administer the study 
drug.  If self-administered by th e patient, the study drug can be given in the thigh or abdomen .  If administered by the careg iver, the sites of injection 
are in the upper arm, thigh, or abdomen  
f Study center to perform visit reminder call to the patient with in 48 prior scheduled home administration date for V5 & V6 
g In case of anaphylaxis, additional samples to be taken (see Sec tion 6.7  and Appendix D) 
h The ±3 day window is related to the IP administration at home and n ot the clinic visit, which should occur no later than 48h after  IP administration 
i Pre- and post-bronchodilator spirometry can be done at Visit 1 (optional Visit 1A) OR Visit 2.   
j  Neutralizing antibody (nAb) testing will occur for all samples that are ADA positive. Samples that are ADA negative will not b e tested for nAb. 
* pre-dose sample  
EOT  End-of-treatment; FU  Follow-up; HCG  Human chorionic gona dotropin; HCP  Healthcare provider; IFU  Instructions for Use; V  Visit; W  Week
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
30(83)  
4.1 Enrollment and screening period 
4.1.1 Enrollment (Visit 1) 
Each patient and caregiver, if applicable, will provide written  informed consent prior to any study 
specific procedures and undergo a ssessments applicable for the visit (see Table 1). 
Patients (and caregiver, if applicable) must sign the Informed Consent Form (ICF) prior to any Visit 
1 procedures.  Registration of the patient’s enrollment via IWR S/IVRS should occur on day when 
other Visit 1 procedures are done. The auto-injector IFU, epine phrine containing device and 
administration questionnaire will  be reviewed as part of the in formed consenting process. 
Visit 1 assessments are primarily concerned with confirmation o f the asthma disease state and the 
requisite level of severity based on background medications. 
A record of physician-diagnosed asthma is required in source do cumentation.  A patient’s verbal 
history suggestive of asthma s ymptoms, but without supporting d ocumentation, is not sufficient to 
satisfy these inclusion criteria. 
Current regular use of ICS prior to enrollment must be document ed in the source.  This 
documentation may be in the form of a recent active medication list as per an HCP note or filled 
prescriptions based on a pharmacy record. 
4.1.2 Re-screening 
Re-screening is allowed only once for any patient. 
Re-screened patients should re -sign the informed consent on the  re-screening Visit 1.  All Visit 1 
procedures should be repeated. 
4.1.2.1  Procedures for patients who exp erience an exacerbation during s creening 
Patients who experience an ast hma exacerbation during screening  should be treated according to 
local medical practice. 
4.2 Treatment period 
Inclusion criteria will be c onfirmed at Visit 2 (Week 0).  Elig ible patients will receive 5 doses of 
benralizumab 30 mg every 4 weeks (Q4W). 
Following a 2 week screening period, eligible patients will rec eive 3 SC doses of benralizumab at 
the study center (Week 0, Week 4, and Week 8). The first inject ion of IP will be done at the study 
center by the HCP at Visit 2 (Week 0). At the Visit 3 (Week 4) and Visit 4 (Week 8) 
administrations, the patient or c aregiver will be asked to admi nister the study drug themselves 
under study center supervision to ensure they understand the pr ocedure and are capable of doing so. 
If the patient is not willing/able to self-administer (or the c aregiver is not willing/able to administer) 
at Visit 4 (Week 8), the patient will be discontinued from IP. At Visit 4 (Week 8) after completion 
of a self-administration, the patient will be given: epinephrin e containing device, IP along with the 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
31(83) Instructions for Use (IFU) and Administration Questionnaire to complete after home 
administration. The final 2 dos es of benralizumab (Week 12 and Week 16) will then be 
administered by the patient or a  caregiver at home. After each of these administrations, the patient 
will return for a scheduled on-site visit within 48 hours. 
The AI Administration Questionnaire (please see Appendix G) is to be filled out by the patient (if 
self-administering) or by the caregiver (if they administered t he IP to the patient).  That person will 
fill out a questionnaire designed to indicate whether the devic e functioned correctly and the dose 
was successfully administered.  Both the administration questio nnaire and the used device are to be 
returned to the study center during each of the clinic visits a fter at-home administration.  Study 
Center Staff will instruct the pa tient or caregiver, if applica ble, on how to complete the 
questionnaire and properly return the device. 
For Visit 2 through Visit 4, all study procedures must be done on the scheduled day of IP injection.  
Urine pregnancy tests must be  done prior to IP administration a t Visits 2 (Week 0), 3 (Week 4), and 
4 (Week 8).  At-home urine pregnan cy tests are to be done by WO CBP prior to IP administration at 
Weeks 12 and 16  and repeated by the study center staff at Visits 5 and 6.  In t he case of a positive 
test, the patient is NOT to administer IP and is to call the st udy center.  Urine pregnancy tests will 
be done at the study center at the EOT visit (Week 20) and the Follow-up visit (Week 28).  
The same person must administer the IP during the entire study,  whether it is the patient or 
caregiver. 
Restrictions as set out in Section 3.5.2 will continue to apply  throughout the treatment period.  In 
case of asthma worsening/exacerbation (see Section 7.3.7), pati ents should be evaluated at the study 
center when feasible. 
Patients will return to the stu dy center at Week 20 for the EOT  visit and at Week 28 for a Follow-
up visit.  If the IP was administered by a caregiver, the careg iver must accompany the patient to 
these visits. 
For premature discontinuation please refer to Section 3.6. 
Completion or early terminati on of the treatment will be regist ered via IWRS/IVRS for each 
patient. 
4.3 Follow-up period 
Patients who complete the treat ment period will be followed for  12 weeks after the last dose of IP 
for the Follow Up visit (Week 28). 
5. STUDY ASSESSMENTS 
Medidata Rave Web Based Data Capture (WBDC) system will be used  for data collection and 
query handling. The investigator will ensure that data are reco rded on the electronic Case Report 
Forms as specified in the study protocol and in accordance with  the instructions provided. 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
32(83) The investigator ensures the accuracy, completeness and timelin ess of the data recorded and of the 
provision of answers to data queries according to the Clinical Study Agreement. The investigator 
will sign the completed electronic Case Report Forms. A copy of  the completed electronic Case 
Report Forms will be archived at the study site. 
5.1 Efficacy assessments 
5.1.1 Spirometry 
General requirements 
Lung function (reversibility, FEV 1 and FVC) at the study center will be measured by spirometry 
using the study centers own equipment.  Spirometry will be perf ormed by the Investigator or 
authorized delegate according to American Thoracic Society/Euro pean Respiratory Society 
(ATS/ERS) guidelines (Miller et al 2005). 
The Principal Investigator or authorized delegate is responsibl e for assuring that the spirometer is in 
a good working condition, calibrated and meets ATS/ERS recommen dations and that the study 
center personnel who will be performing the testing are properl y certified.   
Patients should withhold their SABA medication(s) for at least 6 hours prior to spirometry (see 
Section 3.5.2.1).  LABA therapy (with or without ICS) should be  withheld for 12-24 depending on 
whether the patient is using twice or once daily LABA-containin g therapy, respectively. 
Time for scheduled centre visit spirometry 
Spirometry testing should be done according to the schedule pro vided in Table 1 and Table 2. 
Spirometry technique 
Patients should avoid engaging in strenuous exertion for at lea st 30 minutes prior to spirometry 
measurements.  Patients should avoid eating a large meal for at  least 2 hours prior to spirometry 
measurements at the center.  Forced expiratory maneuvers should  be performed with the patient 
seated in an upright position.  I f this is not comfortable for the patient, standing is permitted.  The 
same position should be used by th e patient for each forced exp iratory maneuver. The head must 
not be tilted during maneuvers and the thorax should be able to  move freely; hence tight clothing 
should be loosened.  A nose-cli p should be used for the maneuve r.  
The forced expiratory maneuvers (FEV 1 and FVC) should start with a maximal inspiration and then 
followed by a fast and forceful expiration that should last for  at least 6 seconds.  It is important to 
encourage the patient to continue the expiration to be fast and  forceful throughout the maneuver.  
Ensure that none of the following has occurred: coughing during  the first second, glottis closure, or 
leak or obstruction of the mouthpiece (by the tongue). 
Multiple forced expiratory efforts (at least 3 but no more than  8) will be performed for each center 
spirometry session and the 1 best effort (highest FEV 1) that meet the ATS/ERS acceptability and 
reproducibility criteria will be r ecorded in the eCRF. The abso lute measurement (for FEV 1 and 
FVC), and the percentage of predicted normal value will be reco rded. The best effort values will be 
based on the one with highest FEV 1.  
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
33(83) 5.1.1.1  Reversibility test and post-BD FEV 1 assessment 
The procedure described in this section refers to the reversibi lity testing at Visit 1 or optional 1A or 
Visit 2. Bronchodilatation can be induced using albuterol (90 μ g metered dose), salbutamol (100 μg 
metered dose) or levalbuterol (45 μg metered dose) up to a maxi mum of 4 inhalations. It is highly 
recommended to use a spacer device  for this procedure. The algo rithm for reversibility testing is 
outlined in Figure 2.  
Figure 2 Reversibility testing algorithm 
 
1 Verify with the patient that the medication restrictions to all ow the reversibility assessment have 
been met (Section 3.5.2)  
 
2 After a gentle and complete expi ration, albuterol, salbutamol o r levalbuterol is inhaled in one breath 
to TLC from a spacer device.  The breath is then held for 5–10 seconds before the patient exhales. 
Four separate inhalations are delivered at approximately 30- second intervals.  Post-BD 
spirometry should be performed 30-60 minutes later. 
 
3 If the patient still has not met reversibility 
criteria at Visit 1 further attempts to demonstrate 
reversibility criteria are allowed at optional Visit 
1A or Visit 2 
 
  
A lower total dose, eg, 2 inhalations instead of 4 
puffs, can be used if there is a concern about any effect on the patient’s heart rate, tremor, or safety. 
Reversibility should be calculated as follows: 
% Reversibility=(post-BD FEV
1- pre BD 
FEV 1)×100 
     p r e - B D  F E V 1 
Record keeping 
A signed and dated copy of the spirometry printout must be kept  at study center for source data 
verification.  The printout must  be marked with the study code,  enrollment code, date and time of 
measurement, visit number.  Record ed data will be entered into the eCRF. 

Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
34(83) 5.1.2 Assessment of self and caregiver administration with the single -use auto-injector 
One of the primary endpoints of interest is the proportion of p atients/caregivers who successfully 
administered benralizumab with t he AI device at home.  A succes sful administration is defined as 
an injection completed and an an swer of “Yes” to all 5 question s in the administration 
questionnaire (please see Appendix G) and satisfactory in vitro  evaluation of the returned devices. 
5.1.3 Assessment of returned single-use auto-injector device through in vitro evaluation 
In addition to the administrati on questionnaire filled out and returned with each at-home 
administered dose, the used A I device will be returned to the S ponsor for in vitro evaluation.  The 
data collected in the in vitro  evaluation of the AI devices falls into 2 categories: 1) Visual  
inspection, and 2) Functional evaluation.  The visual inspectio n will assess the returned devices for 
any visible damage or disassembly, full plunger travel indicati ng a complete dose was expelled, and 
needle guard deployment.  The functional evaluation will challe nge the needle safety guard to 
assess whether it deployed corr ectly and continued to provide p rotection against accidental needle 
stick injuries.  As mentioned in Section 5.1.2, a satisfactory in vitro  evaluation of the returned 
devices and a completed administration questionnaire with an an swer of “Yes” to all 5 questions in 
the questionnaire will constitute a successful administration. Any device defects reported during the 
in vitro evaluation will result i n a full product complaint inv estigation. In the event that the answers 
to one or more of the questions on t he questionnaire indicate t hat the user was unable to complete a 
successful administration, a n evaluation will be performed on t he returned device. The evaluation 
will take into account information provided on the administrati on questionnaire.  If the in vitro 
evaluation of the device shows no observable device defect, the n the unsuccessful administration 
may be classified as a use error and not a device malfunction ( e.g. user removes Autoinjector from 
the injection site before the injection is complete). 
5.2 Safety assessments 
5.2.1 Physical examination  
Physical examination will be done in accordance with schedule p rovided in Table 1and Table  2. 
Baseline data will be collected at Visit 1.  Any new finding(s)  or aggravated existing finding(s), 
judged as clinically significant by the Investigator, will be r eported as an AE as described in 
Section 7.1 
5.2.1.1  Complete physical examination  
The complete physical examination  will include an assessment of the following: general 
appearance, skin, head and neck (including eyes, ears, nose, mo uth, and throat), lymph nodes, 
abdomen, musculoskeletal (incl uding spine and extremities), car diovascular, respiratory, and 
neurological systems.  
5.2.1.2  Brief physical examination  
The brief physical examination w ill include an assessment of th e general appearance, abdomen, 
cardiovascular and respiratory system. For the brief physical e xamination only information on 
whether the assessment was performed or not is to be recorded.  
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
35(83) 5.2.2 Vital signs  
Vital signs (pulse, blood pressure, respiration rate, and body temperature) are to be obtained in 
accordance with schedule provide d in Table 1 and Table 2. 
Body temperature will be measured in Celsius. 
5.2.3 Electrocardiograms  
Electrocardiograms (ECGs) are t o be performed in accordance wit h the schedule provided in Table 
1.  Measurements will be performed on local study center based equipment. 
A 12-lead ECG will be taken in s upine position after the patien t has been resting for at least 5 
minutes.   
A standard ECG with a recomme nded paper speed of 50 mm/second c overing at least 6 sequential 
beats should be used.  The Investigator or authorized delegate will be responsible for the overall 
interpretation and determination of clinical significance of an y potential ECG findings.  In case of 
discrepancy between the Investi gators interpretation and that p rovided by the ECG machine (if 
applicable), the Investigator’s interpretation takes precedence  and should be noted on the printout 
and recorded in the eCRF.  Two identical copies of the ECG will  be produced, quality checked, and 
kept in case of further need for re-evaluation.   
Record keeping 
A signed and dated copy of the ECG printout must be kept at stu dy center for source data 
verification.  The printout must  be marked with the study code,  enrollment code, date and time of 
measurement, visit number. ECG  data and evaluation will be reco rded in the eCRF. 
5.2.4 Laboratory safety assessments 
Safety laboratory tests (list provided in Table 3 below) will b e performed in a central laboratory. 
For information on methods of collection, assessment, labeling,  storage, and shipment of samples 
please refer to the separate Laboratory Manual. Safety samples will be collected in accordance with 
the schedules provided in Table 1 and Table 2 
Hematology and urinalysis will be assessed in line with the sch edules provided in the Table 1 and 
Table 2. 
 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
36(83) Table 3 List of safety laboratory tests 
Clinical chemistry  
(serum or plasma) Haematology/Haemostasis 
(whole blood) Urinalysis 
ALP (Alkaline phosphatase) Hematocrit Appearance 
ALT (alanine aminotransferase) Hemoglobin Blood 
AST (aspartate aminotransferase) Mean corpuscular volume 
(MCV) Color 
Bilirubin, total 
BUN (blood urea nitrogen) Platelet count Glucose 
Calcium Red blood cell (RBC) count Ketones 
Chloride 
Cholesterol, total  WBC count with differential Microscopy including 
WBC/high power field 
(HPF), RBC/HPF 
CO 2 (carbon dioxide)  pH 
Creatinine  Specific gravity 
Gamma-GT (gamma-glutamyl 
transpeptidase)   
Glucose   
Phosphorus   
Potassium   
Sodium   
Uric acid   
Serum concentration a   
a For patients on theophylline or d igoxin (see Section  3.5.2.2)  
 
The Investigator should make an assessment of the available res ults with regard to clinically 
relevant abnormalities. The laboratory results should be signed  and dated and retained at centre as 
source data for laboratory variables. For information on how AE s based on laboratory tests should 
be recorded and reported, see Section 7.3 
NB. In case a subject shows an AST or ALT ≥3xULN and total bilirubin ≥2xULN please 
refer to Appendix C ‘Actions R equired in Cases of Increases in Liver Biochemistry and 
Evaluation of Hy’s Law’, for further instructions.   
5.2.4.1  Pregnancy test  
The following tests are applicab le to female patients only and will be conducted in accordance with 
the schedules provided in Table 1 and Table 2: 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
37(83) x Serum beta-HCG: To be done at screening Visit 1 only for WOCBP (analyzed at central 
laboratory)   
x FSH: To be done at screening Visit 1 only for female patients t o confirm postmenopausal 
status in women <50 years w ho have been amenorrheic for ≥12 mon ths  
x Urine HCG: To be performed at the study center for WOCBP at Vis its 2, 3, and 4 before IP 
administration using a dipstick.  The test will be performed at  home prior to the 2 at-home 
IP administrations, and again at the study center at Visits 5, 6, 7, 8.  A positive urine test 
result must be confirmed with serum beta HCG. 
5.3 Other assessments and procedures 
5.3.1 Weight and height 
Weight and height will be measured, and the BMI will be calcula ted, in accordance with schedules 
provided in Table 1. 
The patient’s weight will be recorded in kilograms and height i n centimeters. 
Weight and height measurements will be performed in light cloth ing and with shoes off. 
5.3.2 Patient-reported outcomes 
5.3.2.1  Asthma Control Questionnaire (ACQ-6) 
The ACQ-6 is a shortened version of  the ACQ that assesses asthm a symptoms (night-time waking, 
symptoms on waking, activity limitation, shortness of breath, w heezing, and short-acting β 2 agonist 
use) omitting the FEV 1 measurement from the original ACQ score. 
Patients are asked to recall how  their asthma has been during t he previous week by responding to 1 
bronchodilator use question and 5 symptom questions. 
Questions are weighted equally and scored from 0 (totally contr olled) to 6 (severely uncontrolled).  
The mean ACQ-6 score is the mean of the responses.  Mean scores  of ≤0.75 indicate well-
controlled asthma, scores be tween 0.75 and ≤1.5 indicate partly  controlled asthma , and a score >1.5 
indicates not well controlled asthma (Juniper et al 2006).  Ind ividual changes of at least 0.5 are 
considered to be clinically meaningful.  The questionnaire will  be completed at the study center in 
accordance with schedule provided in Table 1and Table 2. 
5.3.3 Other screening assessments 
5.3.3.1  Serology 
Hepatitis B surface antige n, hepatitis C antibody : To be done only at screening; test to be 
performed at central laboratory. 
HIV-1 and HIV-2 antibodies : To be done only at screening; tes t to be performed at central  
laboratory. 
Instructions for sample collect ion, processing, storage, and sh ipment can be found in the separate 
Laboratory Manual provided to the study centers. 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
38(83) 5.3.4 Pharmacokinetics 
For the PK analysis, it is important that the date and time of each SC injection is recorded for each 
patient. Instructions for sampl e collection, processing, storag e, and shipment can be found in the 
separate Laboratory Manual provided to the centers.  Samples wi ll be collected according to the 
schedule of study procedures. 
Samples for determina tion of benralizumab concentration in seru m will be analyzed by a central 
laboratory on behalf of AstraZene ca, using a validated bioanaly tical method. Full details of the 
analytical method used will be de scribed in bioanalytical repor t.  
 The PK samples will be retained at AstraZeneca or designee for a maximum of 3 years following 
publication of the CSR to properly  address potential questions from regulatory authorities (RAs). 
 
A summary of PK analysis result s will be reported in the Clinic al Study Report (CSR). 
5.3.5 Pharmacodynamics  
Samples for the analysis of pe ripheral blood eosinophils will b e performed in a central laboratory as 
part of the routine hematology assessment (complete blood count  [CBC]).  
5.3.6 Immunogenicity  
Instructions for immunogenicity (ADA and nAb) sample collection , processing, storage, and 
shipment can be found in the sepa rate Laboratory Manual provide d to the centers. 
The immunogenicity samples will be retained at AstraZeneca or d esignee for a maximum of 3 years 
following publication of the CSR to properly address potential questions from RAs. 
A summary of the analysis will be presented in the CSR. Details  of the analytical method used will 
be described in a bioanalytical report. 
Anti-drug antibodies   
Serum samples for analysis of a nti-drug antibodies (ADA) will b e collected pre-dose at selected 
visits according to the study plan (see Table 2). 
The presence or absence of ADA w ill be determined in the serum samples using validated 
bioanalytical methods. 
Neutralizing antibodies 
Neutralizing antibodies (nAb) testing will occur on all samples  that are ADA positive. Samples that 
are ADA-negative will not be tested for nAb.   
The presence or absence of neutralizing antibodies will be dete rmined using a validated 
bioanalytical method. 
5.3.7 Pharmacogenetics 
Pharmacogenetic samples will not be taken during the study. 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
39(83) 5.3.8 Biomarker analysis 
Samples for biomarker analysis  will not be collected during the  study. 
5.3.9 Handling of biological samples 
5.3.9.1  Labeling and shipment of biological samples 
The Principal Investigator is to ensure that samples are labele d and shipped in accordance with the 
Laboratory Manual and the Biological Substance, Category B Regu lations (materials containing or 
suspected to contain infectious substances that do not meet Cat egory A criteria), see Appendix B 
‘IATA 6.2 Guidance Document’. 
Any samples identified as Infect ious Category A materials are n ot to be shipped and no further 
samples will be taken from the pa tient unless agreed with Astra Zeneca and appropriate labeling, 
shipment, and containment provisions are approved. 
5.3.9.2  Chain of custody of biological samples  
A full chain of custody will be  maintained for all samples thro ughout their lifecycle. 
The Principal Investigator at each study center is to keep full  traceability of collected biological 
samples from the patients while i n storage at the study center until shipment or disposal (where 
appropriate) and is to keep documentation of receipt of arrival  (where applicable). 
The sample receiver is to keep full traceability of the samples  while in storage and during use until 
used or disposed of or until further  shipment and is to keep do cumentation of receipt of arrival. 
AstraZeneca will maintain oversight of the entire life cycle th rough internal procedures, monitoring 
of study centers and auditing of e xternal laboratory providers.  
Samples retained for further use w ill be registered in the Astr aZeneca biobank system during the 
entire life cycle. 
6. MANAGEMENT OF INVESTI GATIONAL PRODUCT 
6.1 Identity of investigational product(s) 
All IP will be manufactured in accordance with Good Manufacturi ng Practice (GMP). 
Benralizumab administered in t he study will be a clear to opale scent, colorless to yellow solution. 
Table 4 Identity of investigational product 
Investigational product Dosage form and strength Manufacturer 
Benralizumab 30 mg/mL solution for injection 
in the single -use auto- injector 
device, 1mL fill volume MedImmune 
 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
40(83) 6.2 Labeling 
Labelling of the IP will be carried out by AstraZeneca or desin gee in accordance with Good 
Manufacturing Practice (GMP) and local regulatory guidelines of  each country participating in the 
study. The labels will fulfil GMP Annex 13 requirements for lab elling. Label text will be translated 
into local language.  
The label will include the following information: 
x study code 
x Investigational product/study dru g dosage form, route of admini stration and quantity of 
dosage units 
x kit ID 
x P Lot ID 
x Expiry date 
x Investigator Name (to be written on the label) 
x E-code (to be written in the label) 
x Sponsor name and contact details 
x Directions for use 
x Storage condition 
x Standard statements required by regulatory authorities 
6.3 Storage 
Benralizumab is to be stored at the study center in a secured f acility with limited access and 
controlled temperature.  The temp erature should be monitored on  a daily basis and documented in 
the temperature monitoring log while IP stored at study center.  
The IP must be kept in the original outer container and under c onditions specified on the label 
(between 2-8°C [36-46°F], protected from the light).   
Patients can transport the IP in uncontrolled temperature condi tions but should return it to a 
refrigerator as soon as possible.  The temperature is not monit ored during storage by the patient; 
standard refrigeration is s ufficient to maintain appropriate te mperatures while the IP is in the 
patient’s possession. 
In the following cases neither the center staff nor the patient  or caregiver should use the affected IP 
and should immediately contact a n AstraZeneca representative fo r further guidance: 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
41(83) x Temperature excursion upon receipt or during storage at the stu dy center 
x Damaged kit upon receipt 
x Damaged AI device 
Damaged IP should be documented via IWRS/IVRS (please refer to IWRS/IVRS manual for 
further details). 
6.4 Accountability 
The study drug provided for this study will be used only as dir ected in the study protocol. 
The study personnel will account for all study drugs dispensed to the patient. 
The monitor will account for all study drugs received at the ce nter, unused study drugs, and for 
appropriate destruction or ret urn of materials to the Sponsor.  Certificates of delivery, destruction, 
and/or return should be signed. 
The patient will be responsible  for refrigerating the product a t home.  The patient will be 
responsible for returning used AI devices and completed adminis tration questionnaires to the study 
center. 
Patients who fail to meet the i nclusion/exclusion criteria  should not, under any circumstances, 
be enrolled or receive study med ication.  There can be no excep tions to this rule. 
6.5 Methods for return of used single-use auto-injector devices 
Study sites will be shipped an a ppropriate number of Bio-bottle s (hard plastic, wide-mouth bottles 
approved for containing and shi pping biohazardous and/or sharps  materials).  Patients who are 
given IP to administer at home will also be given one Bio-bottl e for each of the two doses to be 
administered at home.  The Bio-bottle will be given at the time  the IP is provided to the patient.   
Instruction for Use (IFU) provided to the patient with each IP kit will include instructions on how 
to properly package the used AI device in the Bio-bottle.  Pati ents will be instructed to bring the 
used AI device packaged in the Bio-bottle along with the comple ted administration questionnaire to 
the clinic during next center visit.  
The completed administration que stionnaire and the Bio-bottle c ontaining the used AI will be 
returned to the Sponsor by the clinical site following the Auto -injector Return Working Instruction 
document provided to the study sites.  All site coordinators of  clinical centers participating in the 
study will receive training prior to study start. 
6.5.1 Reporting product complaints 
Any defects with the IP must be reported immediately to the Sit e Monitor.  All defects will be 
communicated to the Sponsor and investigated further with the A straZeneca Supply Chain Group.  
During the investigation of the product complaint, all IP must be stored at labeled conditions 2°C to 
8°C (36°F to 46°F), separated from other IP kits, unless otherw ise instructed. 
Draft Clinical Study Protocol 
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031  
Edition Number 1.0 
Date 23 August 2016 
42(83) 6.5.1.1  Reporting defects 
Product defects may be related to component, product, or packag ing and labeling issues prior to or 
during use.  Product defects should be reported to the Study Mo nitor.  The list below includes, but  
is not limited to, descriptions of product complaints in these 3 categories should be reported as 
defects: 
x Component Issue: Defect in container or dosing mechanism of the IP.  The component 
defect may be damaged, missi ng, or broken.  Component examples include the Autoinjector 
and the prefilled syringe housed within the Autoinjector.  
x Product Issue: Defect in the product itself. The product appearance has  visual 
imperfections such as foreign pa rticles, crystallization, disco loration, turbidity, insufficient 
volume, or anything that does not  apply to the product descript ion in the IFU.  
x Packaging/Labeling Issue: Defect in the packaging or labeling o f the product.  The 
packaging (carton, thermo-fitted tray, or tamper-evident seal) or labeling defects may be 
damaged or unreadable, or the label may be missing.  
6.5.1.2  Single Use Auto-Injector malfunction 
An AI device malfunction is when the AI device appears normal d uring verification of shipment 
and then does not work during administration, e.g., the autoinj ector activated prematurely, the 
autoinjector stalled or did not expel the full volume, needle g uard safety feature did not deploy or 
remain locked, glass syringe breakage, needle bent or broke upo n use. Device malfunctions should 
be reported using the Device Malfunction Return Instruction and  the Study Monitor should be 
notified. 
Site staff will be asked to se nd back malfunctioning devices to  the depot or local sponsor company 
according to local procedures.  A ddress and attention for malfu nctioning device is available in the 
Device Malfunction Return Instruction. 
6.6 Investigational product administ ration and treatment compliance  
The administration of all study drugs (including IPs) should be  recorded in the appropriate sections 
of the Case Report Form (CRF). 
The IP will be administered at the study center for first 3 dos es and at home for following 2 doses.  
IP administration should be done within visit windows as specif ied in 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
43(83) .  All information regarding IP administration will be provided  in the Instruction for Use 
(IFU). 
Before investigational product administration 
Prior to each IP administration at study center: 
x Investigator/authorized delegate will assess injection site as per standards of medical 
care  
x For WOCBP, urine pregnancy test will be done; IP will be admini stered only when the 
result of the test is negative (see Section 5.2.4.1) 
Prior to each IP administration in at-home setting: 
x Investigator/authorized delegate will perform visit reminder ca ll within 48h prior 
scheduled IP administration.  The conversation should include o nly basic information 
and serve as a reminder to the patient about the next scheduled  visit to occur within 48 
hours after home administration. 
x For WOCBP, urine pregnancy test will be done; IP will be admini stered only when the 
result of the test is negative (see Section 5.2.4.1) 
Investigational pro duct administration 
The IP will be administered by the Investigator/authorized dele gate/patient/caregiver as 
specified in Table 2.  If patie nt is not willing or not able to  self-administer (or caregiver is not 
willing/able to administer) at Visit 4 patient will be disconti nued from the IP.  
It is suggested that the site of injection of the IP be rotated  such that the patient receives IP at 
a different anatomical site each time.  Suggested injection sit e rotation sequence is presented 
below (see Figure 3).  In the case when rotation of the injecti on site is not favorable for the 
patient and/or Investigato r, the reason should be recorded in t he source documents.  The 
injection site must be recorded in the source documents and the  eCRF at each treatment visit.  
If IP is self-administered by the patient, the injection should  be done in the abdomen or thigh; 
when the injection is performed by the healthcare provider (HCP ) or caregiver: in the 
abdomen, or thigh or upper arm (site reserved only for injectio ns performed by HCP or 
caregiver - see Figure 3). The s ame person must administer the IP throughout the study, 
whether it is the patient or caregiver. 
Further details on IP administration are provided in the Instru ction for Use (IFU).  
Investigational product administration must be carried out in l ine with the instructions 
provided. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
44(83) Figure 3 Injection sites and rotation scheme 
 
After investigational product administration 
After IP administration the patient should be observed for a mi nimum of 2 hours by the HCP 
(or responsible adult if injection was done at home) for the ap pearance of any acute drug 
reactions. Patient/caregiver will  be trained by the study site on the use of epinephrine 
containing device that will be provided. If IP administration w as performed at home, the 
patient should visit the study centre for the previously schedu led center visit within 48 hours 
after IP administration. 
Conditions requiring investigational product administration res cheduling  
If any of the following occur, t he Investigator should reschedu le the visit and the IP should not 
be administered until t he rescheduled visit:  
x The patient has an intercurrent illness that, in the opinion of  the Investigator, may 
compromise the safety of the patient in the study (eg, viral il lnesses)  
The patient and caregiver, if applicable, should be informed ab out these conditions and 
reminded prior to at-home administration. In case of any doubts  before at-home 
administration, patient should contact study center.  
6.7 Management of investigational product-related reactions 
Prior to the first 3 administrations, which will be performed i n the clinic, patients will have 
had a pre-assessment (ie, vital si gns) prior to IP administrati on, and will be observed after IP 
administration for a minimum of 2 hours for the appearance of a ny acute drug reactions. 
 Study personnel should inform patients that, for subsequent ad ministrations, they should be 
observed for 2 hours after IP administration for the appearance  of any acute drug reactions. As 
with any medication, in case of an anaphylactic reaction at hom e, the patient or caregiver 
should immediately contact an emergency care unit or emergency transportation as per 
standard medical practice, and contact study site personnel.   
Appropriate drugs (eg, epinephrin e, H1 and H2 antihistamines, a nd corticosteroids), and 
medical equipment to treat acute anaphylactic reactions must be  immediately available.  Study 
personnel must be trained to recognize and treat anaphylaxis (L ieberman et al 2010).  Details 
on anaphylaxis management are provided in Appendix D. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
45(83) Anaphylaxis will be defined as a serious reaction that is rapid  in onset and may cause death 
(Simpson et al 2006).  Anaphylaxis typically manifests as 1 of 3 clinical scenarios: 
10. The acute onset of a reaction (minutes to hours) with involveme nt of the skin, 
mucosal tissue, or both, and at l east 1 of the following: a) re spiratory compromise 
or b) reduced blood pressure or symptoms of end-organ dysfuncti on 
11. Two or more of the following that occur rapidly after exposure:  involvement of the 
skin/mucosal tissue, respiratory compromise, reduced blood pres sure or associated 
symptoms, and/or persistent gastrointestinal symptoms 
12. Reduced blood pressure after exposure 
In order to help understand the potential drug-relatedness of a ny acute reaction, a blood 
sample should be drawn during the  event for additional ADA test ing (if not already scheduled 
for this visit).  Serum tryptase or other blood or urine testin g relevant to the diagnosis of 
anaphylaxis may be obtained at a local lab at the discretion of  the Investigator. 
7. SAFETY REPORTING AND MEDICAL MANAGEMENT 
The Principal Investigator is responsible for ensuring that all  staff involved in the study are 
familiar with the content of this section. 
7.1 Definition of adverse events 
An adverse event (AE) is the de velopment of an undesirable medi cal condition or the 
deterioration of a pre-existing medical condition following or during exposure to a 
pharmaceutical product, whether  or not considered causally rela ted to the product.  An 
undesirable medical condition ca n be symptoms (eg, nausea, ches t pain), signs (eg, 
tachycardia, enlarged liver) or the abnormal results of an inve stigation (eg, laboratory 
findings, ECG).  In clinical studies, an AE can include an unde sirable medical condition 
occurring at any time, including run-in or washout periods, eve n if no study treatment has 
been administered. 
The term AE is used to include both serious and non-serious AEs . 
7.2 Definitions of serious adverse event 
A serious adverse event (SAE) is an AE occurring during any stu dy phase (ie, run-in, 
treatment, washout, follow-up), that fulfills 1 or more of the following criteria: 
x Results in death 
x Is immediately life-threatening 
x Requires in-patient hospitali zation or prolongation of existing  hospitalization  
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
46(83) x Results in persistent or signifi cant disability/incapacity or s ubstantial disruption of the 
ability to conduct normal life functions 
x Is a congenital abnormality or birth defect 
x Is an important medical event that may jeopardize the patient o r may require medical 
intervention to prevent 1 of the  outcomes listed above. 
For further guidance on the definition of a SAE, see Appendix A  to the Clinical Study 
Protocol 
7.3 Recording of adverse events 
7.3.1 Time period for collection of adverse events 
Adverse events will be collecte d from the time the patient sign s the informed consent, 
throughout the treatment period and including the follow-up per iod (through Week 28). 
Serious adverse events will be  recorded from the time of inform ed consent. 
7.3.2 Follow-up of unresolved adverse events 
Any AEs that are unresolved at follow-up in the study are follo wed up by the 
Investigator for as long as medically indicated, but without fu rther recording in 
the case report form (CRF). AstraZeneca retains the right to re quest additional 
information for any subject with ongoing AE(s)/SAE(s) at the en d of the study, if 
judged necessary. 
7.3.3 Variables  
The following variables will be collect for each AE; 
x AE (verbatim) 
x The date when the A E started and stopped 
x Maximum intensity of the AE 
x Whether the AE is serious or not 
x Investigator causality rating against the Investigational Produ ct (yes or no) 
x Action taken with regard to investigational product 
x AE caused  subject’s withdrawal from study (yes or no ) 
x Outcome. 
In addition, the following variables will be collected for SAEs : 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
47(83) x Date AE met criteria for serious AE 
x Date Investigator became aware of serious AE 
x AE is serious due to 
x Date of hospitalization 
x Date of discharge 
x Probable cause of death 
x Date of death 
x Autopsy performed 
x Causality assessment in relation to Study procedure(s) 
x Description of AE 
It is important to distinguish between serious and severe AEs.  Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Sec tion 7.2.  An AE of severe 
intensity need not necessarily be considered serious.  For exam ple, nausea that persists for 
several hours may be considered s evere nausea, but not a SAE un less it meets the criteria 
shown in Section 7.2. On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild stroke but would be a SAE w hen it satisfies the criteria 
shown in Section 7.2. 
7.3.4 Causality collection 
The Investigator will assess causal relationship between Invest igational Product and each 
Adverse Event, and answer ‘yes’ or ‘no’ to the question ‘Do you  consider that there is a 
reasonable possibility that the event may have been caused by t he investigational product?’ 
For SAEs causal relationship will also be assessed for other me dication and study procedures.  
Note that for SAEs that could be associated with any study proc edure the causal relationship is 
implied as ‘yes’. 
A guide to the interpretation of the causality question is foun d in Appendix A to the Clinical 
Study Protocol. 
7.3.5 Adverse events based on signs and symptoms 
All AEs spontaneously reported by the subject or reported in re sponse to the open question 
from the study personnel: ‘Have you had any health problem s since the previous visit/you 
were last asked?’ , or revealed by observation will be collected and recorded in the CRF. 
When collecting AEs, the recording of diagnoses is preferred (w hen possible) to recording a 
list of signs and symptoms.  However, if a diagnosis is known a nd there are other signs or 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
48(83) symptoms that are not generally part of the diagnosis, the diag nosis and each sign or symptom 
will be recorded separately. 
7.3.6 Adverse events based on  examinations and tests 
The results from protocol manda ted laboratory tests and vital s igns will be summarized in the 
clinical study report.  Deterioration as compared to baseline i n protocol-mandated laboratory 
values, vital signs should there fore only be reported as AEs if  they fulfil any of the SAE 
criteria or are the reason for di scontinuation of treatment wit h the investigational product. 
If deterioration in a laboratory value/vital sign is associated  with clinical signs and symptoms, 
the sign or symptom will be report ed as an AE and the associate d laboratory result/vital sign 
will be considered as additional information.  Wherever possibl e the reporting Investigator 
uses the clinical, rather than t he laboratory term (eg, anaemia  versus low haemoglobin value). 
In the absence of clinical signs or symptoms, clinically releva nt deteriorations in non-
mandated parameters should be reported as AE(s). 
Any new or aggravated clinically relevant abnormal medical find ing at a physical examination 
as compared with the baseline a ssessment will be reported as an  AE. 
7.3.7 Disease progression 
When collecting AEs, the recording of diagnoses is preferred wh en possible to the recording 
of signs or symptoms. Asthma signs or symptoms such as wheeze, cough, chest tightness, 
breathlessness etc. will be recorded as AEs only when: 
x The sign or symptom is serious according to definition, see Sec tion 7.2 
x The patient discontinues the st udy due to the sign or symptom. 
x The sign or symptom is new to the patient or is not consistent with the patient’s pre-
existing asthma history as judged by the Investigator. 
Asthma exacerbation should be recorded as an AE or SAE only if it fulfills any of the above 
criteria. 
7.3.8 Hy’s Law 
Cases where a subject shows ele vations in liver biochemistry ma y require further evaluation 
and occurrences of AST or ALT ≥3xULN together with total biliru bin ≥2xULN may need to 
be reported as SAEs.  Please refe r to Appendix C for further in struction on cases of increases 
in liver biochemistry and evaluation of Hy’s Law. 
7.4 Reporting of serious adverse events 
All SAEs have to be reported, whe ther or not considered causall y related to the investigational 
product, or to the study procedure( s).  All SAEs will be record ed in the CRF. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
49(83) If any SAE occurs in the course of the study, then Investigator s or other site personnel inform 
the appropriate AstraZeneca representatives within 1 day, ie, i mmediately but no later than 
24 hours  of when he or she becomes aware of it. 
The designated AstraZeneca representative works with the Invest igator to ensure that all the 
necessary information is provided to t he AstraZeneca Patient Sa fety data entry site within 1  
calendar day  of initial receipt for fatal and life threatening events and within 5 calendar  
days of initial receipt for all other SAEs. 
For fatal or life-threatening adverse events where important or  relevant information is missing, 
active follow-up is undertaken immediately.  Investigators or o ther site personnel inform 
AstraZeneca representatives of any follow-up information on a p reviously reported SAE 
within 1 calendar day ie, immediately but no later than 24 hours of when he or she becomes 
aware of it. 
Once the Investigators or other site personnel indicate an AE i s serious in the WBDC system, 
an automated email alert is sent to the designated AstraZeneca representative. 
If the WBDC system is not available, then the Investigator or o ther study site personnel 
reports a SAE to the appropriate AstraZeneca representative by telephone. 
The AstraZeneca representative will advise the Investigator/stu dy site personnel how to 
proceed.  
The reference document for defi nition of expectedness/listednes s is the Investigator’s 
Brochure (IB) for the AstraZeneca drug. 
7.5 Overdose 
x An overdose with associated AEs will be recorded as the AE diag nosis/symptoms on 
the relevant AE modules in the CRF and on the Overdose CRF modu le 
x An overdose without associated symptoms will be reported on the  Overdose CRF 
module only 
If an overdose on an AstraZeneca study drug occurs in the cours e of the study, then 
Investigators or other center personnel will inform appropriate  AstraZeneca representatives 
within 1 day, ie, immediately but no later than 24 hours from when he or she becomes aware 
of it. 
The designated AstraZeneca representative will work with the  Investigator to ensure that all 
relevant information is provided to t he AstraZeneca Patient Saf ety data entry site. 
For overdoses associated with a SAE, standard reporting timelin es apply, see Section 7.4 For 
other overdoses, reporting should be done within 30 days. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
50(83) 7.6 Pregnancy 
All pregnancies and outcomes of pregnancy should be reported to  AstraZeneca. 
7.6.1 Maternal exposure 
If a subject becomes pregnant during the course of the study in vestigational product should be 
discontinued immediately.  
Pregnancy itself is not regarded as an adverse event unless the re is a suspicion that the 
investigational product under study may have interfered with th e effectiveness of a 
contraceptive medication.  Congenital abnormalities/birth defec ts and spontaneous 
miscarriages should be reporte d and handled as SAEs.  Elective abortions without 
complications should not be handled as AEs.   The outcome of all pregnancies (spontaneous 
miscarriage, elective termina tion, ectopic pregnancy, normal bi rth or congenital abnormality) 
should be followed up and documented even if the subject was di scontinued from the study. 
If any pregnancy occurs in the course of the study, then the In vestigator or other site personnel 
informs the appropriate AstraZene ca representatives within 1day  ie, immediately but no later 
than 24 hours of when he or she becomes aware of it. 
The designated AstraZeneca representative works with the Invest igator to ensure that all 
relevant information is provided to t he AstraZeneca Patient Saf ety data entry site within 1 or 5 
calendar days for SAEs (see Section7.4) and within 30 days for all other pregnancies. 
The same timelines apply when outcome information is available.  
The PREGREP module in the CRF is used to report the pregnancy a nd the PREGOUT is used 
to report the outcome of the pregnancy. 
7.6.2 Paternal exposure  
Male patients should refrain from  fathering a child or donating  sperm during the study and for 
16 weeks (5 half-lives) following the last dose. 
Pregnancy of the patient’s part ners will not be  considered an A E.  However, the outcome of 
all pregnancies (spontaneous misca rriage, elective termination,  ectopic pregnancy, normal 
birth, or congenital abnormality) should be followed up and doc umented for conceptions 
occurring from the date of the first administration of IP until  16 weeks (5 half-lives) after the 
last administration of IP. 
8. STATISTICAL ANALYSES BY ASTRAZENECA 
8.1 Statistical considerations 
Analyses will be performed by AstraZeneca or its representative s. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
51(83) The SAP will be prepared prior to first patient enter treatment  period and any subsequent 
amendments will be documented, w ith final amendments completed prior to data base lock  
8.2 Sample size estimate  
No hypotheses will be tested statistically. Approximately 120 p atients will receive the 
treatment to allow approximately 100 patients to complete the s tudy. It is based upon a 
targeted recruitment with an adj ustment to account for a 17% pa tient’s drop-out rate.  
8.3 Definitions of analysis sets 
Three patient populations are defi ned below: All patients’ anal ysis set, Full analysis set (FAS), 
and Pharmacokinetics analysis set.  
Patients must have provided their informed consent. If no signe d informed consent is collected 
(major protocol deviation (PD)), then the patient will be exclu ded from all analysis sets 
defined below.  8.3.1 All patients analysis set 
The all patients analysis set wi ll comprise all patients screen ed for the study and will be used 
for the reporting of disposition and screening failures. 
8.3.2 Full analysis set 
All patients receiving at least one IP will be included in the full analysis set (FAS), 
irrespective of their protocol  adherence and continued particip ation in the study.  Patients who 
withdraw consent to participate  in the study will be included u p to the date of their study 
termination.  
All analyses, except for PK analysis, will be performed using t he FAS. 
8.3.3 Pharmacokinetic analysis set 
All patients who received benralizumab and from whom PK blood s amples were collected are 
assumed not to be affected by factors such as protocol violatio ns will be included in the PK 
analysis dataset.  Those patients who had at least 1 quantifiab le serum PK observation post 
first dose will be included in the  PK analysis dataset. All PK summaries will be based on this 
analysis set. 
8.4 
Variables for analyses 
8.4.1 Calculation or derivation of primary endpoints  
8.4.1.1  Primary endpoints 
The primary endpoints are as follows:  
x Proportion of patients/caregivers who successfully administered  benralizumab with an 
AI device at home among those who have been deemed by the Princ ipal Investigator to 
be suitable for at-home administ ration and are still in the stu dy at Week 12 or Week 
16.  A successful administration i s defined as an injection com pleted, an answer of 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
52(83) “Yes” to all 5 questions in the administration questionnaire (s ee Appendix G), and the 
autoinjector adequately passed the visual inspection and functi onal tests.  
Patients/caregivers who are unwilling to self-administer at Wee k 8 will not be 
considered as failures, but will be counted as unsuitable for a t-home administration and 
follow the premature IP Discontinuation (IPD) procedure.  
x Proportion of returned AI devices used to administer benralizum ab at home that have 
been evaluated as functional among all returned AI devices used  to administer 
benralizumab at home.  A functiona l AI device is defined as an answer of “Yes” to all 
the questions in the visual inspection and function tests. Devi ces that are not returned 
for evaluation will be exc luded from analysis. 
x Proportion of returned AI devices used to administer benralizum ab at home and in the 
clinic that have been reported as malfunctioning (Product Compl aints). 
The first 2 endpoints above will be calculated at Weeks 12 and 16, while the third endpoint 
will be obtained at each of the pos t-treatment periods (Weeks 0 , 4, 8, 12, and 16). 
In addition, the following variables will be calculated among a ll patients/caregivers who have 
been deemed by the Investigator to be suitable for at-home admi nistration at Week 8 and are 
still in the study at Week16:  
x Proportion of patients/caregivers wh o successfully administered  benralizumab with an 
AI device at both Weeks 12 and 16, and 
x Proportion of patients/caregivers who returned an AI device use d to administer 
benralizumab at home and evaluated as functional at both Weeks 12 and 16. 
8.4.2 Calculation or derivation of  efficacy variable(s) 
8.4.2.1  Asthma Control Questionnaire (ACQ-6) 
The outcome variable for ACQ-6 will be the change in mean score  from baseline (Week 0) to 
each of the post-treatment periods. 
Patients will be categorized acc ording to their asthma control responder status using the 
following limits (Juniper et al 2005) at the end of treatment ( EOT) visit: 
x ACQ-6  EOT – baseline) ≤ -0.5 → Improvement 
x -0.5< ACQ-6 (EOT – baseline) < 0.5 → No change 
x ACQ-6 (EOT – baseline)  ≥ 0.5 → Deterioration 
An ACQ-6 responder will be defi ned as a patient who had improve ment on ACQ-6, ie, an 
ACQ-6 responder variable takes valu e 1 if change from baseline to end of treatment in 
ACQ-6 ≤ -0.5 and 0 otherwise. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
53(83) Furthermore, patients will also be categorized according to the ir ACQ-6-defined asthma 
control status at the end of treatment using the following scor e thresholds (Juniper et al 2006) 
at the EOT visit: 
x ACQ-6 (EOT ) ≤ 0.75 → Well controlled 
x 0.75< ACQ-6 (EOT) < 1.5 → Partly controlled 
x ACQ-6 (EOT) ≥ 1.5 → not well controlled 
8.4.3 Calculation or derivation of safety variable(s) 
8.4.3.1  Safety variables 
The following safety data will be collected: AEs, vital signs, physical examination, 
hematology, clinical chemistry, urinalysis. 
Change from baseline (Week 0) t o each post-treatment time point  where scheduled 
assessments were made will be calculated for relevant measureme nts.   
8.4.3.2  Other significant adverse events 
During the evaluation of the AE data, an AstraZeneca medically qualified expert will review 
the list of AEs that were not reported as SAEs and discontinuat ions due to AEs. 
Based on the expert’s judgment, significant AEs of particular c linical importance may, after 
consultation with the Global Patient Safety Physician, be consi dered other significant AEs 
(OAEs) and reported as such in the CSR. 
Examples of these are marked hematological and other laboratory  abnormalities, and certain 
events that lead to interventi on (other than those already clas sified as serious), dose reduction, 
or significant additional treatment. 
8.4.4 Calculation or derivation of pha rmacokinetic variables 
No formal PK data analysis is pl anned due to the limited sampli ng schedule and variations in 
sampling time post self-administration.  Benralizumab serum con centrations will be 
summarized at each visit using  descriptive statistics.  The PK results will be provided in the 
CSR. 
8.4.5 Calculation or derivation of i mmunogenicity variables 
ADA assessments will be conducted utilizing a tiered approach ( screen, confirm, titer).  
8.5 Methods for statistical analyses 
The analysis of the primary endpoints will include all data cap tured during Weeks 12 and 16 
(for Product Complaints with addition of Weeks 0, 4 and 8) whil e secondary endpoints will 
include all data captured during  the 20-week treatment period, and up to follow-up (where 
applicable), unless the patient withdraws consent to study part icipation, regardless of whether 
study treatment was prematurely discontinued, or delayed, and/o r irrespective of protocol 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
54(83) adherence. All efficacy analyse s will be performed using an Int ent-to-Treat (ITT) approach 
based on the FAS. For consistency , demographic and baseline cha racteristics will be presented 
using FAS. Safety objectives will also be analyzed using the FA S. 
8.5.1 Primary and secondary analysis method(s) 
No formal statistical analyses will be performed.  Primary and secondary endpoints will be 
summarized descriptively and all data will be listed.  Exact 95 % confidence interval estimates 
will also be presented for the primary endpoints.   
8.5.1.1  Analysis methods for pharmacokinetic variables 
The PK analyses will be performed at or under the guidance of A straZeneca Research and 
Development. 
Benralizumab serum concentrations will be summarized using desc riptive statistics at each 
visit.  No formal PK data analysis  is planned due to sparse sam pling and variations of 
sampling time following benrali zumab self-administrations.  Obs erved serum concentrations 
of benralizumab for each individual will be listed by visit to confirm benralizumab 
administration.  Serum concentrat ions of benralizumab will be p rovided in the CSR. 
8.5.1.2  Analysis methods for blood eosinophil levels 
Blood eosinophil levels will be summarized using standard summa ry statistics and plots at 
each visit. 
8.5.1.3  Analysis method for immunogenicity variables 
The potential association of ADA wit h safety will be evaluated.   The association of ADA titer 
with benralizumab concentration and blood eosinophil levels wil l be evaluated for ADA-
positive patients only.  
8.5.2 Analysis methods for safety variables 
AEs will be summarized by means of counts by study period (trea tment period and follow-up 
period). AEs will be listed for e ach patient and summarized by System Organ Class (SOC) 
and Preferred Term (PT) assig ned to the event by MedDRA.   
Laboratory data for hematology and clinical chemistry will be s ummarized. The frequency of 
changes with respect to normal ranges between baseline and each  post-treatment time point 
will be tabulated. Frequencies of  clinically noteworthy values (defined in the SAP) occurring 
during the clinical study will also be given. Shifts from norma l to abnormal between baseline 
and each post-baseline time poi nt will be evaluated for urinaly sis. Similar summaries will be 
performed for vital signs.  Shifts from normal to abnormal betw een baseline and follow-up 
will be evaluated for the p hysical examination. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
55(83) 8.5.3 Subgroup analysis 
To explore the uniformity of the  estimates, the primary endpoin ts will also be summarized 
separately for patients self-administering and caregivers who a re administering to the patient 
for the first 2 endpoints.  
9. STUDY AND DATA MANAGEMENT BY ASTRAZENECA 
9.1 Training of study center personnel 
Before the first patient is entered into the study, an AstraZen eca representative will review and 
discuss the requirements of the C linical Study Protocol and rel ated documents with the 
investigational staff and also tra in them in any study specific  procedures and WBDC, 
IWRS/IVRS, PROs, and other systems to be utilized. 
The Principal Investigator will ensure that appropriate trainin g relevant to the study is given to 
all of these staff, study patient and caregiver if applicable, and that any new information 
relevant to the performance of this study is forwarded to the s taff involved.  
The Principal Investigator will maintain a record of all indivi duals involved in the study 
(medical, nursing and other staff). 
9.2 Monitoring of the study 
During the study, an AstraZeneca representative will have regul ar contacts with the study 
center, including visits to: 
x Provide information and support to the Investigator(s) 
x Confirm that facilities remain acceptable 
x Confirm that the investigationa l team is adhering to the protoc ol, that data are being 
accurately and timely recorded in t he CRFs, that biological sam ples are handled in 
accordance with the Laboratory Manual and that study drug accou ntability checks are 
being performed 
x Perform source data verification (a comparison of the data in t he CRFs with the 
patient’s medical records at the hospital or practice, and othe r records relevant to the 
study) including verification of informed consent of participat ing patients.  This will 
require direct access to all origi nal records for each patient (eg, clinic charts) 
x Ensure withdrawal of informed cons ent to the use of the patient ’s biological samples is 
reported and biological samples are identified and disposed of/ destroyed accordingly, 
and the action is documented, and reported to the patient. 
The AstraZeneca representative will be available between visits  if the Investigator(s) or other 
staff at the center needs information and advice about the stud y conduct. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
56(83) 9.2.1 Source data 
Please refer to the Clinical Study Agreement (CSA) for location  of source data. 
9.2.2 Recording of data  
A Web-based Data Capture (WBD C) system will be used for data co llection and query 
handling. Trained study center personnel will be responsible fo r entering data on the 
observations, tests, and assessments specified in the CSP into the WBDC system and 
according to eCRF instructions.  The eCRF instructions will als o guide the study center in 
performing data entry. 
Data entered in the WBDC system will be immediately saved to a central database and 
changes tracked to provide an audit trail.  The data will then be source data verified, 
reviewed/queried and updated as  needed.  The data will be valid ated as defined in the Data 
Management Plan.  The Investigator will ensure that data are re corded on the eCRFs as 
specified in the CSP and in accord ance with the instructions pr ovided.  
The Investigator ensures the accuracy, completeness, and timeli ness of the data recorded and 
of the provision of answers to data  queries according to the CS A. The Investigator will sign 
the completed eCRFs. A copy of t he completed eCRFs will be arch ived at the study center. 
9.2.3 Study agreements 
The Principal Investigator at each/the study center should comp ly with all the terms, 
conditions, and obligations of the C linical Study Agreement (CS A), or equivalent, for this 
study.  In the event of any inconsistency between this CSP and the CSA, the terms of CSP 
shall prevail with respect to t he conduct of the study and the treatment of patients and in all 
other respects, not relating to study conduct or treatment of p atients, the terms of the CSA 
shall prevail. 
Agreements between AstraZeneca and the Principal Investigator s hould be in place before any 
study-related procedures can take  place, or patients are enroll ed. 
9.2.4 Archiving of study documents 
The Investigator follows the principles outlined in the CSA. 
9.3 Study timetable and end of study 
The end of the study is defined as ‘the last visit of the last patient undergoing the study. 
The study is expected to start in Q4 2016 and to end by Q4 2017  
The study may be terminated at individual study centers if the study procedures are not being 
performed according to Good Clinical Practice (GCP), or if recr uitment is slow. AstraZeneca 
may also terminate the entire study prematurely if concerns for  safety arise within this study 
or in any other study with benralizumab. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
57(83) 9.4 Data management by AstraZeneca 
Data management will  be performed by AstraZeneca Data Managemen t Centre staff 
according to the Data Management Plan. Adverse events and medic al/surgical history will be 
classified according to the terminology of the latest version t he Medical Dictionary for 
Regulatory Activities (MedDRA). Medications will be classified according to the AstraZeneca 
Drug Dictionary. Classification c oding will be performed by the  Medical Coding Team at the 
AstraZeneca Data Management Centre. 
 
The data collected through third party sources will be obtained  and reconciled against study 
data.  
Adverse events and medical/surgical history will be classified according to the terminology of 
the latest version MedDRA. Medications will be classified accor ding to the AstraZeneca Drug 
Dictionary. All coding will be performed by the Medical Coding Team at the AstraZeneca 
Data Management Centre. 
Data queries will be raised for inconsistent, impossible or mis sing data. All entries to the study 
database will be available in an audit trail. 
The data will be validated as de fined in the data management pl an (DMP). Quality control 
procedures will be applied to each stage of data handling to en sure that all data are reliable 
and have been processed correctly. T he DMP will also clarify th e roles and responsibilities of 
the various functions and personnel involved in the data manage ment process. 
When all data have been coded, va lidated, signed and locked, cl ean file will be declared. Any 
treatment revealing data may th ereafter be added and the final database will be locked. 
Serious adverse even t reconciliation 
Serious adverse event reconciliation reports are produced and r econciled with the Patient 
Safety database and/or the investigational site. 
Data associated with human biological samples 
Data associated with biological samples will be transferred fro m laboratory(ies) internal or 
external to AstraZeneca. 
10. ETHICAL AND REGULATORY REQUIREMENTS 
10.1 Ethical conduct of the study 
The study will be performed in accordance with ethical principl es that have their origin in the 
Declaration of Helsinki and are c onsistent with International C onference on 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
58(83) Harmonisation/Good Clinical Practice, applicable regulatory req uirements and the 
AstraZeneca policy on Bioethics and Human Biological Samples. 
10.2 Subject data protection 
The Informed Consent Form (ICF), will incorporate (or, in some cases, be accompanied by a 
separate document incorporating) wording that complies with rel evant data protection and 
privacy legislation. 
10.3 Ethics and regulatory review 
An Ethics Committee (EC) should a pprove the final study protoco l, including the final version 
of the ICF, and any other writ ten information and/or materials to be provided to the patients.  
The Investigator will ensure the distribution of these document s to the applicable EC, and to 
the study center staff. 
The opinion of the EC should be given in writing.  The Investig ator should submit the written 
approval to AstraZeneca before e nrollment of any patient into t he study.  
The EC should approve all advertis ing used to recruit patients for the study. 
AstraZeneca should approve any modifications to the ICF that ar e needed to meet local 
requirements. 
If required by local regulations, the protocol should be re-app roved by the EC annually. 
Before enrollment of any patient into the study, the final stud y protocol, including the final 
version of the ICF is approved by the national regulatory autho rity or a notification to the 
national regulatory authority is done, according to local regul ations. 
AstraZeneca will handle the distribution of any of these docume nts to the national regulatory 
authorities. 
AstraZeneca will provide Regulatory Authorities, ECs, and Princ ipal Investigators with safety 
updates/reports according to local requirements, including SUSA Rs (Suspected Unexpected 
Serious Adverse Reactions), where relevant. 
Each Principal Investigator is  responsible for providing the EC s/Institutional Review Board 
(IRB) with reports of any serious and unexpected adverse drug r eactions from any other study 
conducted with the IP.  AstraZe neca will provide this informati on to the Principal Investigator 
so that he/she can meet these reporting requirements. 
10.4 Informed consent 
The Principal Investigator(s) at each study center  will: 
x Ensure each patient or legal gua rdian is given full and adequat e oral and written 
information about the nature, purpose, possible risk and benefi t of the study (before 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
59(83) any study procedures are performed) as per local requirements.  The ICF needs to be 
adjusted as per local requirements. 
x Ensure each patient or legal guardian is notified that they are  free to discontinue from 
the study at any time. 
x Ensure that each patient or legal guardian is given the opportu nity to ask questions and 
allowed time to consider the information provided.  
x Ensure each patient or legal g uardian provides signed and dated  Informed Consent 
before conducting any procedure specifically for the study. 
x Ensure the original, signed Informed Consent(s) is/are stored i n the Investigator’s 
Study File and kept for a period that is complaint with GCP/loc al regulatory 
requirements, whichever is longer. 
x Ensure a copy of the signed Informed Consent Form is given to t he patient. 
x Ensure that any incentives for patients who participate in the study as well as any 
provisions for patients harmed as a consequence of study partic ipation are described in 
the Informed Consent Form that is approved by an Ethics Committ ee. 
10.5 Changes to the protocol and informed consent form 
Study procedures will not be changed without the mutual agreeme nt of the International 
Coordinating Investigator and AstraZeneca. 
If there are any substantial changes to the study protocol, the n these changes will be 
documented in a study protocol a mendment and where required in a new version of the study 
protocol (Revised CSP). 
The amendment is to be approved by the relevant EC and if appli cable, also the national 
regulatory authority approval, before implementation.  Local re quirements are to be followed 
for revised protocols. 
AstraZeneca will distribute any subsequent amendments and new v ersions of the protocol to 
each Principal Investigator(s) . For distribution to EC see Sect ion 10.3. 
If a protocol amendment requires a change to a study center’s I CF, AstraZeneca and the study 
center’s EC are to approve the revised ICF before the revised f orm is used.  
If local regulations require, any administrative change will be  communicated to or approved 
by each EC. 
10.6 Audits and inspections 
Authorised representatives of Ast raZeneca, a regulatory authori ty, or an EC may perform 
audits or inspections at the stud y center, including source dat a verification.  The purpose of an 
audit or inspection is to systematically and independently exam ine all study-related activities 
and documents, to determine wheth er these activities were condu cted, and data were recorded, 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
60(83) analysed, and accurately reported according to the protocol, GC P guidelines of the 
International Conference on Harmonisation (ICH), and any applic able regulatory 
requirements.  The Investigator will contact AstraZeneca immedi ately if contacted by a 
regulatory agency or other body about an inspection or an audit  at the study center. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
61(83)  
11. LIST OF REFERENCES 
ATS 2005 
American Thoracic Society/European Respiratory Society. ATS/ERS  recommendations for 
standardized procedures for the online and offline measurement of exhaled lower respiratory 
nitric oxide and nasal nitric  oxide, 2005. Am J Respir Crit Car e Med 2005;171:912–930 
Bateman et al 2010 
Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears  MR, et al. Overall asthma 
control: The relationship between current control and future ri sk. J Allergy Clin Immunol . 
2010;125:600-8. 
Bleecker et al 2016 
Eugene R Bleecker, J Mark FitzGerald, Pascal Chanez, Alberto Pa pi, Steven F Weinstein, 
Peter Barker, Stephan ie Sproule, Geoffrey Gilmartin, Magnus Aur ivillius, Viktoria 
Werkström, Mitchell Goldman, on behalf of the SIROCCO study inv estigators. Efficacy and 
safety of benralizumab for patients with severe asthma uncontro lled with high-dosage inhaled 
corticosteroids and long-acting b2-agonists (SIROCCO): a random ised, multicentre, 
placebo-controlled phase 3 trial. Lancet Respir Med. 2016 Sept 05 (online) 
Bousquet et al 1990 
Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enand er I, et al. Eosinophilic 
inflammation in asthma. N Engl J Med 1990;323:1033-9. 
Busse et al 2010 
Busse WW,  Katial R, Gossage D, Sari S, Wang B, Kolbeck B, et a l. Safety profile, 
pharmacokinetics, and biologic activity of MEDI-563, an anti–IL -5 receptor a antibody, in a 
phase I study of patients with mild asthma. J Allergy Clin Immu nol 2010;125:1237-44.  
Castro et al 2014 
Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse W W, et al. Benralizumab, an 
anti-interleukin-5 receptor al pha monoclonal antibody, for unco ntrolled eosinophilic asthma. 
Lancet Respir Med 2014; 2:879–90 
Di Franco et al 2003 
Di Franco A, Bartoli ML, Carnevali S, Cianchetti S, Bacci E, De nte FL, et al. Analysis of 
sputum cell counts during spont aneous moderate exacerbations of  asthma in comparison to the 
stable phase. J Asthma 2003;40:155-62. 
FitzGerald et al 2016 
J Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, Stepha nie Korn, Ken Ohta, 
Marek Lommatzsch, Gary T Ferguson, William W Busse, Peter Barke r, Stephanie Sproule, 
Geoffrey Gilmartin, Viktoria Werkström, Magnus Aurivillius, Mit chell Goldman, on behalf of 
the CALIMA study investigators. Benralizumab, an anti–interleuk in-5 receptor α monoclonal 
antibody, as add-on treatment for patients with severe, uncontr olled, eosinophilic asthma 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
62(83) (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 
2016 Sept 05 (online) 
GINA 2016 
Global Strategy for Asthma Mana gement and Prevention, Global In itiative for Asthma 
(GINA) Updated 2016. Available from: URL: http://ginasthma.org.  Accessed May 2016. 
 
Gossage et al 2012 
Gossage DL, Laviolette M, Gauvreau GM, Leigh R, Kolbeck R, Wu1 Yet al. Depletion of 
airway eosinophils by benralizumab an anti-Il5 receptor alpha m onoclonal antibody. Am J 
Respir Crit Care Med. 185;2012:A3961. 
Green et al 2002 
Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradd ing P, et al. Asthma 
exacerbations and sputum eosinophil counts: a randomized contro lled trial. Lancet. 
2002;360(9347):1715–21. 
Jayaram et al 2006 
Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemière C, Pizzic hini E, et al. Determining 
asthma treatment by monitoring sputum cell counts: effect on ex acerbations. Eur Respir J 
2006;27:483-94. 
Juniper et al 2005 
Juniper EF, Svensson K, Mörk AK, Ståhl E. Measurement propertie s and interpretation of 
three shortened versions of the  asthma control questionnaire. R espir Med 2005;99:553-8. 
Juniper et al 2006 
Juniper EF, Bousquet J, Abetz L, Bateman ED, The GOAL Committee . Identifying ‘well-
controlled’ and ‘not well-controlle d’ asthma using the Asthma C ontrol Questionnaire. Respir 
Med 2006;100:616-21. 
Kerstjens et al 2012 
Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in 
asthma poorly controlled with standard combination therapy. N E ngl J Med 2012;367:1198-
207. 
Kolbeck et al 2012 
Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschrode r MM, et al. MEDI-
563, a humanized anti–IL-5 recept or a mAb with enhanced antibod y-dependent cell-mediated 
cytotoxicity function. J Allergy Clin Immuno 2010;125:1344-53. 
Laviolette et al 2013 
Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse  WW, Wenzel S, Wu Y, 
Datta V, Kolbeck R, Molfino NA, Effects of benralizumab on airw ay eosinophils in asthma 
with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov; 132 (5): 1086–1096.e5. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
63(83) Lieberman et al 2010 
Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Berns tein DI, et al. The 
diagnosis and management of anaph ylaxis practice parameter: 201 0 update. J Allergy Clin 
Immunol 2010 ;126:477-80.e1-42. 
Louis et al 2000 
Louis R, Lau LC, Bron AO, Roldaan AC, Radermerker M, Djukanovic  R. The relationship 
between airways inflammation and asthma severity. Am J Respir C rit Care Med 2000;161:9-
16. 
Masoli et al 2004 
Masoli M, Holt S, Weatherall M, Beasley R. The dose-response re lationship of inhaled 
corticosteroids in asthma. C urr Allergy Asthma Rep 2004;4:144-8 . 
Miller et al 2005 
Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi  R, et al. General 
considerations for lung function Testing. Eur Respir J 2005;26: 153-61. 
Molfino et al 2011 
Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular  and clinical rationale 
for therapeutic targeting of interleukin-5 and its receptor. Cl in Exp Allergy 2011;42:712-37.  
Molfino et al 2012 
Molfino NA, Nowak R, Silverman RA, Rowe BH, Smithline H, Khan F , et al Reduction in the 
number and severity of exacerba tions following acute severe ast hma: results of a placebo-
controlled, randomized clinical tr ial with benralizumab. Am J R espir Crit Care Med 2012: 
185:A2753. 
NAEPP 2007 
NAEPP 2007, National Asthma Education Prevention Program. Expert Panel Report 
3:Guidelines for the Diagnosis and Management of Asthma . Available: 
http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.  
Pavord et al 2012 
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et  al. Mepolizumab for 
severe eosinophilic asthma (DREAM):a multicenter, double-blind,  placebo-controlled trial. 
Lancet 2012;380:651-9. 
Quanjer et al 2012 
Quanjer PH, Stanojevic S, Cole TJ, Baur X, L Hall GL, Culver B,  et al. Multi ethnic reference 
values for spirometry for the 3-95 year age range: the global l ung function 2012 equations. 
Eur Resp J 2012;40:1324-43. 
Scott and Wardlaw 2006 
Scott KA, Wardlaw AJ. Eosinophi lic airway disorders. Semin Resp ir Crit Care Med 2006; 
27:128-33. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
64(83) Saito et al 2015 
Yuji W, Kawai H, Nakanishi T Ascending Single Intravenous And S ubcutaneous Dose 
Studies Of Benralizumab In Japanese Healthy Male Volunteers: Sa fety, Tolerability, 
Pharmacokinetics And Pharmacodynamics. C36. ASTHMA THERAPY II. May 1, 2015, 
A4270-A4270 
Simpson et al 2006 
Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes  in asthma: assessment 
and identification using induced sputum. Respirology 2006;11:54 -61. 
Sorkness et al 2008 
Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung  KF, et al. Lung 
function in adults with stable but severe asthma: air trapping and incomplete reversal of 
obstruction with bronchodilation. J Appl Physiol 2008;104:394–4 03. 
Takatsu et al 1994 
Takatsu K, Takaki S, Hitoshi Y. Interleukin-5 and its receptor system: implications in the 
immune system and inflammation. Adv Immunol 1994;57:145-90. 
Toba et al 1999 
Toba K, Koike T, Shibata A, Hashimoto S, Takahashi M, Masuko M,  et al. Novel technique 
for the direct flow cytofluorimetric analysis of human basophil es in unseparated blood and 
bone marrow, and the character ization of phenotype and peroxida se of human basophiles. 
Cytometry. 1999;35:249-59. 
Wenzel 2012 
Wenzel SE. Asthma phenotypes: th e evolution from clinical to mo lecular approaches. Nat 
Med 2012;18:716-25.  
Zhang and Wenzel 2007 
Zhang JY, Wenzel SE. Tissue and BAL based biomarkers in asthma.  Immunol Allergy Clin 
North Am 2007;27:623-32. 
Clinical Study Protocol  
Drug Substance Benralizumab (Medi-563)  Study Code D3250C00031 
Version 1.0 
Date 23 August 2016 
65(83)  